Overcoming	O
limitations	O
of	O
current	O
antiplatelet	O
drugs	O
:	O
A	O
concerted	O
effort	O
for	O
more	O
profitable	O
strategies	O
of	O
intervention	O

Platelets	O
play	O
a	O
central	O
role	O
in	O
the	O
pathophysiology	O
of	O
atherothrombosis	O
,	O
an	O
inappropriate	O
platelet	O
activation	O
leading	O
to	O
acute	O
ischemic	O
complications	O
(	O
acute	B-DS
myocardial	I-DS
infarction	I-DS
,	O
ischemic	B-DS
stroke	I-DS
).	O

In	O
view	O
of	O
this	O
,	O
platelets	O
are	O
a	O
major	O
target	O
for	O
pharmacotherapy	O
.	O

Presently	O
,	O
the	O
main	O
classes	O
of	O
antiplatelet	O
agents	O
approved	O
for	O
the	O
use	O
in	O
such	O
complications	O
are	O
aspirin	O
and	O
fhienopyridines	O
.	O

Although	O
antiplatelet	O
treatment	O
with	O
these	O
two	O
types	O
of	O
drugs	O
,	O
alone	O
or	O
in	O
combination	O
,	O
leads	O
to	O
a	O
significant	O
reduction	O
of	O
non	O
-	O
fatal	O
myocardial	B-DS
infarction	I-DS
(−	O
32	O
%),	O
non	O
-	O
fatal	O
stroke	B-DS
(−	O
25	O
%),	O
and	O
of	O
cardiovascular	O
death	O
(−	O
17	O
%),	O
a	O
residual	O
risk	O
persists	O
.	O

Newer	O
antiplatelet	O
agents	O
have	O
addressed	O
some	O
,	O
but	O
not	O
all	O
,	O
these	O
limitations	O
.	O

Vis	O
-	O
à	O
-	O
vis	O
their	O
net	O
clinical	O
benefit	O
,	O
the	O
higher	O
potency	O
of	O
some	O
of	O
them	O
is	O
associated	O
with	O
a	O
rise	O
in	O
bleeding	O
complications	O
.	O

Moreover	O
,	O
newer	O
fhienopyridines	O
do	O
not	O
show	O
advantages	O
over	O
and	O
above	O
the	O
older	O
ones	O
as	O
to	O
reduction	O
of	O
stroke	B-DS
.	O

A	O
concerted	O
effort	O
that	O
takes	O
into	O
consideration	O
clinical	O
,	O
genetic	O
,	O
and	O
laboratory	O
information	O
is	O
increasingly	O
recognized	O
as	O
a	O
major	O
direction	O
to	O
be	O
pursued	O
in	O
the	O
area	O
.	O

The	O
well	O
-	O
established	O
road	O
signs	O
of	O
clinical	O
epidemiology	O
will	O
provide	O
major	O
information	O
to	O
define	O
newer	O
potentially	O
useful	O
targets	O
for	O
platelet	O
pharmacology	O
.	O

Introduction	O

Thrombotic	O
(	O
ischemic	O
)	O
complications	O
of	O
atherosclerosis	B-DS
(	O
acute	B-DS
coronary	I-DS
syndrome	I-DS
(	O
ACS	B-DS
),	O
acute	B-DS
myocardial	I-DS
infarction	I-DS
(	O
AMI	B-DS
),	O
ischemic	B-DS
stroke	I-DS
)	O
are	O
the	O
leading	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
Western	O
countries	O
.	O

Following	O
atherosclerotic	O
plaque	O
disruption	O
/	O
endothelial	O
cell	O
detachment	O
,	O
circulating	O
platelets	O
,	O
exposed	O
to	O
a	O
highly	O
thrombogenic	O
environment	O
,	O
become	O
activated	O
(	O
1	O
).	O

As	O
shown	O
in	O
Table	O
I	O
,	O
a	O
series	O
of	O
soluble	O
agonists	O
(	O
ADP	O
,	O
thromboxane	O
A2	O
(	O
T	O
×	O
A2	O
),	O
serotonin	O
(	O
5	O
-	O
HT	O
),	O
and	O
thrombin	B-GP
)	O
recruit	O
and	O
activate	O
additional	O
platelets	O
(	O
2	O
,	O
3	O
).	O

Upon	O
activation	O
,	O
glycoprotein	B-GP
(	O
Gp	B-GP
)	O
IIb	O
/	O
IIIa	O
(	O
αIIbβ3	B-GP
integrin	I-GP
)	O
mediates	O
platelet	O
aggregation	O
and	O
spreading	O
by	O
means	O
of	O
fibrinogen	B-GP
bridges	O
,	O
which	O
,	O
once	O
converted	O
to	O
fibrin	B-GP
,	O
ultimately	O
contribute	O
to	O
thrombus	O
stabilization	O
(	O
4	O
).	O

This	O
leads	O
to	O
the	O
formation	O
of	O
platelet	O
-	O
rich	O
thrombi	B-GP
that	O
,	O
occluding	O
the	O
arterial	O
lumen	O
and	O
impairing	O
blood	O
-	O
flow	O
and	O
oxygen	O
supply	O
,	O
cause	O
acute	O
ischemia	B-DS
(	O
5	O
).	O

Platelet	O
activation	O
:	O
agonists	O
and	O
signal	O
transduction	O
.	O

Agonist	O

Receptor	O
(	O
s	O
)	O

Effect	O
(	O
s	O
)	O

Comments	O

ADP	O

Gaq	B-GP
-	I-GP
coupled	I-GP
P2Y1	I-GP
;	O
Gai	B-GP
-	I-GP
coupled	I-GP
P2Y12	I-GP

P2Y1	B-GP
:	O
shape	O
change	O
;	O
P2Y12	B-GP
:	O
aggregation	O

P2Y12	B-GP
amplifies	O
aggregation	O
induced	O
by	O
5	O
-	O
HT	O
,	O
T	O
×	O
A2	O
,	O
and	O
thrombin	B-GP

T	O
×	O
A2	O

TPa	B-GP
;	O
TPb	B-GP
(	O
secondary	O
)	O

Shape	O
change	O
;	O
platelet	O
recruitment	O
;	O
platelet	O
aggregation	O

In	O
endothelial	O
cells	O
,	O
COX	B-GP
-	I-GP
1	I-GP
-	O
derived	O
PGH2	O
is	O
converted	O
into	O
PGI2	O
,	O
a	O
strong	O
antiaggregating	O
and	O
vasodilating	O
agent	O

Thrombin	B-GP

PAR	B-GP
-	I-GP
1	I-GP
;	O
PAR	B-GP
-	I-GP
4	I-GP
(	O
secondary	O
);	O
GpIbα	B-GP

Shape	O
change	O
;	O
ADP	O
and	O
T	O
×	O
A2	O
secretion	O
;	O
P	B-GP
-	I-GP
selectin	I-GP
expression	O
;	O
αIIbβ3	B-GP
integrin	I-GP
receptor	I-GP
;	O
platelet	O
activation	O

PAR	B-GP
-	I-GP
1	I-GP
and	O
P2Y12	B-GP
cross	O
-	O
reaction	O
(	O
via	O
Gαq	B-GP
and	O
Gai	B-GP
-	I-GP
coupled	I-GP
receptors	I-GP
)	O

Serotonin	O

5HT	B-GP
-	I-GP
2A	I-GP
receptors	I-GP

Shape	O
change	O
;	O
platelet	O
recruitment	O
;	O
retention	O
of	O
fibrinogen	B-GP
and	O
thrombospondin	B-GP
on	O
the	O
platelet	O
surface	O

Implicated	O
in	O
shear	O
-	O
induced	O
platelet	O
aggregation	O
and	O
thrombus	O
propagation	O

The	O
transduction	O
of	O
the	O
ADP	O
signal	O
involves	O
its	O
interaction	O
with	O
two	O
platelet	B-GP
receptors	I-GP
belonging	O
to	O
the	O
P2	O
purinergic	O
family	O
,	O
the	O
Gαq	B-GP
-	I-GP
coupled	I-GP
receptor	I-GP
P2Y1	B-GP
and	O
the	O
Gαi	B-GP
-	I-GP
coupled	I-GP
receptor	I-GP
P2Y12	B-GP
.	O

The	O
concomitant	O
activation	O
of	O
both	O
the	O
Gαq	B-GP
and	O
Gαi	B-GP
pathways	O
by	O
ADP	O
is	O
needed	O
for	O
platelet	O
aggregation	O
to	O
occur	O
.	O

Signaling	O
from	O
the	O
P2Y1	B-GP
receptor	I-GP
causes	O
platelet	O
shape	O
change	O
and	O
rapid	O
transient	O
aggregation	O
,	O
whereas	O
the	O
signaling	O
from	O
the	O
P2Y12	B-GP
receptor	I-GP
facilitates	O
sustained	O
irreversible	O
aggregation	O
and	O
stimulates	O
surface	O
expression	O
of	O
the	O
pro	O
-	O
inflammatory	O
P	B-GP
-	I-GP
selectin	I-GP
(	O
6	O
).	O

In	O
addition	O
,	O
the	O
P2Y12	B-GP
receptor	I-GP
plays	O
a	O
critical	O
role	O
in	O
the	O
amplification	O
of	O
platelet	O
aggregation	O
induced	O
by	O
agents	O
other	O
than	O
ADP	O
,	O
including	O
5	O
-	O
HT	O
,	O
T	O
×	O
A2	O
,	O
and	O
thrombin	B-GP
.	O

Together	O
,	O
these	O
contribute	O
to	O
thrombus	O
growth	O
and	O
stability	O
(	O
5	O
).	O

Key	O
messages	O

Platelets	O
are	O
a	O
major	O
target	O
for	O
pharmacotherapy	O
in	O
cardiovascular	B-DS
disease	I-DS
.	O

In	O
spite	O
of	O
a	O
significant	O
antithrombotic	O
effect	O
,	O
current	O
antiplatelet	O
drugs	O
have	O
major	O
limitations	O
.	O

Newer	O
antiplatelet	O
agents	O
have	O
addressed	O
some	O
but	O
not	O
all	O
the	O
limitations	O
of	O
the	O
current	O
antiplatelet	O
drugs	O
.	O

T	O
×	O
A2	O
,	O
generated	O
from	O
arachidonic	O
acid	O
by	O
cyclooxygenase	B-GP
1	I-GP
(	O
COX	B-GP
-	I-GP
1	I-GP
)	O
and	O
T	B-GP
×	I-GP
synthase	I-GP
,	O
further	O
amplifies	O
platelet	O
activation	O
.	O

COX	B-GP
-	I-GP
1	I-GP
converts	O
arachidonic	O
acid	O
into	O
prostaglandin	O
endoperoxides	O
PGG2	O
and	O
PGH2	O
,	O
the	O
latter	O
being	O
,	O
in	O
turn	O
,	O
transformed	O
by	O
T	B-GP
×	I-GP
synthase	I-GP
into	O
T	O
×	O
A2	O
,	O
a	O
potent	O
amplifier	O
of	O
platelet	O
aggregation	O
with	O
vasoconstrictive	O
properties	O
.	O

At	O
the	O
site	O
of	O
the	O
atheroma	O
rupture	O
,	O
platelet	O
-	O
released	O
T	O
×	O
A2	O
leads	O
to	O
downstream	O
micro	O
-	O
vessel	O
contraction	O
and	O
thrombus	O
propagation	O
(	O
7	O
).	O

In	O
addition	O
to	O
its	O
role	O
in	O
coagulation	O
,	O
thrombin	B-GP
at	O
extremely	O
low	O
concentrations	O
is	O
one	O
of	O
the	O
major	O
platelet	O
activators	O
(	O
8	O
).	O

Human	B-OG
platelets	O
express	O
two	O
cell	O
surface	O
G	B-GP
-	I-GP
protein	I-GP
-	I-GP
coupled	I-GP
protease	I-GP
-	I-GP
activated	I-GP
receptors	I-GP
(	O
PARs	B-GP
)	O
for	O
thrombin	B-GP
:	O
PAR	B-GP
-	I-GP
1	I-GP
and	O
PAR	B-GP
-	I-GP
4	I-GP
.	O

By	O
binding	O
the	O
hirudin	B-GP
-	O
like	O
extracellular	O
amino	O
terminal	O
domain	O
(	O
the	O
so	O
-	O
called	O
thrombin	B-GP
receptor	I-GP
),	O
thrombin	B-GP
activates	O
platelets	O
and	O
smooth	O
muscle	O
cells	O
,	O
thus	O
promoting	O
platelet	O
pro	O
-	O
coagulant	O
activity	O
,	O
shape	O
change	O
,	O
secretion	O
and	O
release	O
of	O
agonists	O
(	O
ADP	O
and	O
T	O
×	O
A2	O
),	O
expression	O
of	O
P	B-GP
-	I-GP
selectin	I-GP
,	O
activation	O
of	O
the	O
αIIbβ3	B-GP
integrin	I-GP
receptor	I-GP
,	O
and	O
aggregation	O
.	O

Thrombin	B-GP
also	O
binds	O
to	O
GpIbα	B-GP
on	O
the	O
surface	O
of	O
platelets	O
,	O
thought	O
to	O
act	O
as	O
a	O
co	O
-	O
factor	O
that	O
localizes	O
the	O
enzyme	O
on	O
the	O
platelet	O
surface	O
and	O
accelerates	O
the	O
hydrolysis	O
of	O
PAR	B-GP
-	I-GP
1	I-GP
(	O
9	O
).	O

PAR	B-GP
-	I-GP
1	I-GP
and	O
P2Y12	B-GP
cross	O
-	O
react	O
in	O
platelet	O
activation	O
,	O
and	O
Gαq	B-GP
and	O
Gαi	B-GP
-	I-GP
coupled	I-GP
receptors	I-GP
are	O
involved	O
in	O
this	O
process	O
.	O

Thrombin	B-GP
-	O
dependent	O
platelet	O
aggregation	O
is	O
mediated	O
in	O
part	O
by	O
secreted	O
ADP	O
,	O
acting	O
on	O
the	O
Gαi	B-GP
-	I-GP
linked	I-GP
ADP	I-GP
receptor	I-GP
.	O

By	O
blocking	O
Gαq	B-GP
via	O
PAR	B-GP
-	I-GP
1	I-GP
and	O
Gβi	B-GP
via	O
P2Y12	B-GP
,	O
combined	O
inhibition	O
of	O
thrombin	B-GP
and	O
P2Y12	B-GP
receptors	I-GP
leads	O
to	O
a	O
synergistic	O
inhibitory	O
effect	O
on	O
thrombin	B-GP
-	O
induced	O
platelet	O
aggregation	O
(	O
10	O
).	O

5	O
-	O
HT	O
is	O
a	O
vasoconstrictor	O
agent	O
that	O
binds	O
to	O
5HT	B-GP
-	I-GP
2A	I-GP
receptors	I-GP
and	O
amplifies	O
the	O
platelet	O
response	O
by	O
stimulating	O
shape	O
change	O
and	O
enhancing	O
platelet	O
recruitment	O
at	O
sites	O
of	O
injury	B-DS
(	O
3	O
).	O

It	O
may	O
also	O
play	O
a	O
pro	O
-	O
coagulant	O
role	O
by	O
promoting	O
the	O
retention	O
of	O
fibrinogen	B-GP
and	O
thrombospondin	B-GP
on	O
the	O
platelet	O
surface	O
.	O

Intraplatelet	O
5	O
-	O
HT	O
stores	O
are	O
implicated	O
in	O
shear	O
-	O
induced	O
platelet	O
aggregation	O
and	O
thrombus	O
propagation	O
(	O
3	O
).	O

Antiplatelet	O
agents	O
in	O
clinical	O
practice	O
:	O
efficacy	O
,	O
safety	O
,	O
limitations	O
(	O
Figure	O
1	O
)	O

Three	O
main	O
classes	O
of	O
antiplatelet	O
agents	O
are	O
licensed	O
for	O
treatment	O
of	O
atherothrombosis	O
:	O
acetyl	O
salicylic	O
acid	O
(	O
aspirin	O
),	O
P2Y12	B-GP
inhibitors	O
(	O
ticlopidine	O
,	O
clopidogrel	O
,	O
prasugrel	O
,	O
cangrelor	O
,	O
ticagrelor	O
),	O
and	O
GpIIb	B-GP
/	I-GP
Ilia	I-GP
receptor	I-GP
antagonists	O
(	O
abciximab	O
,	O
eptifibatide	O
,	O
and	O
tirofiban	O
)	O
(	O
11	O
).	O

While	O
the	O
last	O
-	O
mentioned	O
are	O
only	O
employed	O
intravenously	O
in	O
ACS	B-DS
in	O
combination	O
with	O
other	O
antithrombotic	O
agents	O
(	O
their	O
effect	O
being	O
rather	O
unpredictable	O
when	O
administered	O
orally	O
),	O
the	O
former	O
two	O
classes	O
are	O
widely	O
used	O
chronically	O
.	O

Platelet	O
activation	O
pathways	O
and	O
drug	O
molecular	O
targets	O
.	O

Thrombin	B-GP
binds	O
to	O
PAR	B-GP
-	I-GP
1	I-GP
receptor	I-GP
,	O
which	O
leads	O
to	O
shape	O
change	O
,	O
phospholipase	B-GP
C	I-GP
(	O
PLC	B-GP
)	O
activation	O
,	O
thromboxane	O
A2	O
(	O
T	O
×	O
A2	O
)	O
generation	O
,	O
and	O
activation	O
of	O
the	O
glycoprotein	B-GP
(	O
GP	B-GP
)	O
IIb	O
/	O
IIIa	O
receptor	O
,	O
resulting	O
in	O
sustained	O
platelet	O
aggregation	O
.	O

Cyclooxygenase	B-GP
(	B-GP
COX	I-GP
)-	I-GP
l	I-GP
catalyzes	O
the	O
production	O
of	O
T	O
×	O
A2	O
,	O
a	O
potent	O
platelet	O
aggregator	O
,	O
generated	O
by	O
platelets	O
activated	O
by	O
thrombin	B-GP
and	O
other	O
agonists	O
.	O

Adenosine	O
5	O
'-	O
diphosphate	O
(	O
ADP	O
)	O
binds	O
to	O
its	O
7	O
-	O
transmembrane	O
domain	O
receptors	O
,	O
P2Y1	B-GP
and	O
P2Y12	B-GP
,	O
to	O
activate	O
platelets	O
.	O

P2Y1	B-GP
is	O
coupled	O
to	O
Gαq	B-GP
and	O
G12	B-GP
.	O

Gαq	B-GP
is	O
linked	O
to	O
a	O
signaling	O
pathway	O
involving	O
PLC	B-GP
activation	O
,	O
resulting	O
in	O
a	O
rise	O
in	O
the	O
intracellular	O
calcium	O
concentration	O
([	O
Ca	O
+	O
2	O
]	O
i	O
)	O
and	O
protein	B-GP
kinase	I-GP
C	I-GP
(	O
PKC	B-GP
)	O
activation	O
,	O
leading	O
to	O
GP	B-GP
IIb	I-GP
/	O
IIIa	O
activation	O
and	O
transient	O
platelet	O
aggregation	O
.	O

G12	B-GP
mediates	O
platelet	O
shape	O
change	O
.	O

P2Y12	B-GP
is	O
linked	O
to	O
Gai	B-GP
-	O
coupled	O
signaling	O
cascades	O
associated	O
with	O
adenylcyclase	B-GP
(	O
Ac	B-GP
)	O
down	O
-	O
regulation	O
and	O
decreased	O
cyclic	O
-	O
3	O
',	O
5	O
'-	O
monophosphate	O
(	O
cAMP	O
)	O
production	O
,	O
which	O
mediates	O
GP	B-GP
IIb	I-GP
/	O
IIIa	O
receptor	O
activation	O
,	O
leading	O
to	O
sustained	O
platelet	O
aggregation	O
.	O

Aspirin	O

Owing	O
to	O
its	O
efficacy	O
and	O
favorable	O
cost	O
-	O
effectiveness	O
,	O
aspirin	O
is	O
the	O
mainstay	O
treatment	O
for	O
all	O
atherothrombotic	O
conditions	O
.	O

The	O
efficacy	O
of	O
aspirin	O
lies	O
in	O
its	O
ability	O
to	O
inhibit	O
irreversibly	O
platelet	O
COX	B-GP
-	I-GP
1	I-GP
(	O
by	O
acetylating	O
a	O
serine	O
located	O
near	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
)	O
and	O
,	O
in	O
turn	O
,	O
T	O
×	O
A2	O
formation	O
(	O
12	O
).	O

A	O
recent	O
meta	O
-	O
analysis	O
by	O
the	O
Antithrombotic	O
Trialists	O
’	O
Collaboration	O
(	O
13	O
)	O
assessed	O
the	O
role	O
of	O
aspirin	O
in	O
primary	O
(	O
95	O
,	O
000	O
subjects	O
at	O
low	O
cardiovascular	O
risk	O
)	O
and	O
secondary	O
prevention	O
(	O
17	O
,	O
000	O
patients	O
at	O
medium	O
/	O
high	O
risk	O
)	O
and	O
showed	O
that	O
,	O
while	O
in	O
high	O
-	O
risk	O
conditions	O
the	O
advantages	O
of	O
aspirin	O
outweigh	O
the	O
inherent	O
bleeding	O
hazard	O
,	O
in	O
primary	O
prevention	O
aspirin	O
is	O
associated	O
with	O
an	O
absolute	O
benefit	O
of	O
0	O
.	O
06	O
%/	O
year	O
,	O
too	O
exiguous	O
as	O
compared	O
to	O
the	O
0	O
.	O
03	O
%	O
increase	O
in	O
major	O
bleedings	O
.	O

Ticlopidine	O

Ticlopidine	O
was	O
the	O
first	O
agent	O
of	O
the	O
thienopyridine	O
class	O
shown	O
both	O
to	O
prevent	O
the	O
interaction	O
of	O
ADP	O
with	O
its	O
platelet	O
purinergic	B-GP
receptor	I-GP
and	O
to	O
determine	O
the	O
inhibition	O
of	O
the	O
binding	O
of	O
fibrinogen	B-GP
to	O
the	O
αIIbβ3	B-GP
integrin	I-GP
(	O
14	O
).	O

In	O
subjects	O
with	O
a	O
history	O
of	O
cerebrovascular	O
events	O
,	O
ticlopidine	O
was	O
superior	O
to	O
placebo	O
and	O
to	O
aspirin	O
in	O
the	O
reduction	O
of	O
stroke	B-DS
,	O
AMI	B-DS
,	O
or	O
vascular	O
death	O
(	O
15	O
).	O

In	O
addition	O
,	O
the	O
combination	O
of	O
ticlopidine	O
with	O
aspirin	O
was	O
successful	O
in	O
ACS	B-DS
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
with	O
stent	O
implantation	O
(	O
16	O
).	O

Diarrhea	O
,	O
neutropenia	B-DS
,	O
aplastic	B-DS
anemia	I-DS
,	O
and	O
thrombotic	B-DS
thrombocytopenic	I-DS
purpura	I-DS
are	O
the	O
main	O
limitations	O
for	O
a	O
wide	O
-	O
spread	O
use	O
of	O
ticlopidine	O
.	O

Clopidogrel	O

The	O
thienopyridine	O
prodrug	O
clopidogrel	O
irreversibly	O
binds	O
the	O
P2Y12	B-GP
platelet	I-GP
receptor	I-GP
after	O
a	O
two	O
-	O
step	O
activation	O
by	O
cytochrome	B-GP
P450	I-GP
(	O
CYP	B-GP
)	O
liver	O
isoenzymes	O
.	O

While	O
the	O
CAPRIE	O
trial	O
(	O
about	O
20	O
,	O
000	O
subjects	O
)	O
(	O
17	O
)	O
and	O
a	O
Cochrane	O
systematic	O
review	O
(	O
18	O
)	O
showed	O
that	O
in	O
patients	O
with	O
a	O
history	O
of	O
AMI	B-DS
,	O
stroke	B-DS
,	O
or	O
symptomatic	O
peripheral	B-DS
arterial	I-DS
disease	I-DS
(	O
PAD	B-DS
),	O
clopidogrel	O
administered	O
alone	O
was	O
only	O
marginally	O
superior	O
to	O
aspirin	O
(	O
RRR	O
8	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
043	O
)	O
in	O
preventing	O
vascular	O
events	O
,	O
a	O
significantly	O
higher	O
efficacy	O
has	O
been	O
shown	O
for	O
the	O
‘	O
dual	O
antiplatelet	O
therapy	O
'.	O

The	O
CURE	O
(	O
19	O
)	O
and	O
the	O
CREDO	O
(	O
20	O
)	O
studies	O
established	O
the	O
superiority	O
of	O
clopidogrel	O
in	O
combination	O
with	O
aspirin	O
versus	O
aspirin	O
alone	O
in	O
ACS	B-DS
and	O
in	O
ACS	B-DS
with	O
PCI	O
,	O
respectively	O
.	O

Low	O
response	O
to	O
aspirin	O
or	O
clopidogrel	O

Although	O
antiplatelet	O
treatment	O
in	O
high	O
-	O
risk	O
patients	O
significantly	O
lowers	O
non	O
-	O
fatal	O
AMI	B-DS
(	O
32	O
%),	O
non	O
-	O
fatal	O
stroke	B-DS
(	O
25	O
%),	O
and	O
cardiovascular	O
death	O
(	O
17	O
%),	O
a	O
residual	O
vascular	O
risk	O
persists	O
.	O

After	O
an	O
AMI	B-DS
or	O
a	O
stroke	B-DS
,	O
in	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
,	O
10	O
%-	O
20	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
an	O
ischemic	O
event	O
develop	O
recurrent	O
events	O
in	O
spite	O
of	O
their	O
antiplatelet	O
treatment	O
(	O
21	O
).	O

Compared	O
to	O
aspirin	O
-	O
sensitive	O
patients	O
,	O
the	O
residual	O
platelet	O
reactivity	O
in	O
subjects	O
on	O
antiplatelet	O
therapy	O
correlates	O
with	O
a	O
higher	O
cardiovascular	O
risk	O
and	O
predicts	O
recurrent	O
thrombotic	O
events	O
(	O
22	O
).	O

In	O
the	O
HOPE	O
study	O
,	O
aspirin	O
-	O
treated	O
patients	O
in	O
the	O
highest	O
quartile	O
of	O
the	O
urinary	O
excretion	O
of	O
T	O
×	O
A2	O
metabolite	O
had	O
a	O
1	O
.	O
8	O
-	O
fold	O
higher	O
vascular	O
risk	O
than	O
those	O
in	O
the	O
lowest	O
quartiles	O
(	O
23	O
).	O

A	O
meta	O
-	O
analysis	O
(	O
24	O
)	O
evaluated	O
the	O
relation	O
between	O
a	O
low	O
laboratory	O
response	O
to	O
clopidogrel	O
and	O
the	O
clinical	O
outcome	O
in	O
≈	O
4	O
,	O
500	O
patients	O
with	O
coronary	B-DS
artery	I-DS
disease	I-DS
(	O
CAD	B-DS
)	O
and	O
PCI	O
.	O

Several	O
methods	O
were	O
used	O
to	O
assess	O
platelet	O
response	O
to	O
therapy	O
,	O
and	O
26	O
.	O
4	O
%	O
of	O
patients	O
showed	O
as	O
low	O
responders	O
to	O
clopidogrel	O
.	O

These	O
patients	O
showed	O
a	O
higher	O
risk	O
of	O
death	O
/	O
ischemic	O
events	O
as	O
compared	O
to	O
that	O
of	O
patients	O
in	O
whom	O
a	O
normal	O
response	O
was	O
documented	O
.	O

Although	O
often	O
secondary	O
to	O
a	O
poor	O
compliance	O
(	O
25	O
),	O
a	O
low	O
treatment	O
response	O
('	O
failure	O
')	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
an	O
incomplete	O
inhibition	O
of	O
platelet	O
function	O
(	O
26	O
).	O

Concomitant	O
clinical	O
conditions	O
(	O
diabetes	B-DS
mellitus	I-DS
,	O
inflammation	O
,	O
hypercoagulable	O
states	O
,	O
low	O
fibrinolytic	O
potential	O
),	O
high	O
pretreatment	O
platelet	O
reactivity	O
(	O
observed	O
in	O
ACS	B-DS
or	O
in	O
subjects	O
with	O
high	O
BMI	O
),	O
an	O
increased	O
platelet	O
turn	O
-	O
over	O
,	O
and	O
the	O
simultaneous	O
administration	O
of	O
some	O
drugs	O
(	O
drug	O
interaction	O
and	O
/	O
or	O
inadequate	O
drug	O
absorption	O
)	O
are	O
common	O
,	O
major	O
determinants	O
of	O
a	O
low	O
response	O
to	O
clopidogrel	O
or	O
to	O
aspirin	O
(	O
21	O
,	O
27	O
).	O

The	O
possibility	O
that	O
,	O
in	O
addition	O
to	O
such	O
conditions	O
,	O
genetic	O
variations	O
play	O
a	O
role	O
in	O
a	O
low	O
response	O
to	O
aspirin	O
or	O
to	O
clopidogrel	O
has	O
also	O
been	O
documented	O
.	O

Different	O
haplotypes	O
of	O
COX	B-GP
-	I-GP
1	I-GP
significantly	O
correlate	O
with	O
the	O
response	O
to	O
aspirin	O
and	O
with	O
T	O
×	O
A2	O
generation	O
in	O
patients	O
with	O
stable	O
coronary	B-DS
artery	I-DS
disease	I-DS
(	O
28	O
).	O

A	O
variety	O
of	O
polymorphisms	O
in	O
the	O
CYP2C19	B-GP
gene	O
(	O
most	O
often	O
the	O
CYP2C19	B-GP
*	O
2	O
),	O
associated	O
with	O
a	O
20	O
%-	O
25	O
%	O
production	O
of	O
inactive	O
metabolite	O
,	O
diminish	O
the	O
response	O
to	O
clopidogrel	O
.	O

Among	O
subjects	O
under	O
treatment	O
with	O
clopidogrel	O
for	O
a	O
previous	O
vascular	O
event	O
,	O
carriers	O
of	O
these	O
polymorphisms	O
have	O
a	O
50	O
%	O
higher	O
risk	O
of	O
cardiovascular	O
death	O
,	O
AMI	B-DS
,	O
or	O
stroke	B-DS
(	O
29	O
).	O

Among	O
clopidogrel	O
-	O
treated	O
patients	O
,	O
carriers	O
of	O
at	O
least	O
one	O
allele	O
associated	O
with	O
the	O
loss	O
of	O
or	O
a	O
reduced	O
function	O
in	O
the	O
CYP2C19	B-GP
gene	O
had	O
a	O
higher	O
than	O
normal	O
occurrence	O
of	O
fatal	O
and	O
non	O
-	O
fatal	O
coronary	O
thrombotic	O
events	O
,	O
as	O
well	O
as	O
of	O
stent	O
thrombosis	O
(	O
29	O
).	O

In	O
the	O
same	O
study	O
population	O
,	O
polymorphic	O
alleles	O
of	O
a	O
gene	O
modulating	O
clopidogrel	O
absorption	O
(	O
ABCB1	B-GP
)	O
have	O
been	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
cardiovascular	O
events	O
at	O
1	O
-	O
year	O
follow	O
-	O
up	O
as	O
compared	O
to	O
wild	O
-	O
type	O
subjects	O
.	O

Overcoming	O
limitations	O
of	O
aspirin	O

Changing	O
doses	O
and	O
schedules	O
of	O
aspirin	O

Because	O
inhibition	O
of	O
platelet	O
aggregation	O
by	O
aspirin	O
is	O
irreversible	O
,	O
the	O
possibility	O
of	O
monitoring	O
the	O
entry	O
of	O
newly	O
formed	O
platelets	O
into	O
the	O
circulation	O
(	O
i	O
.	O
e	O
.	O
the	O
platelet	O
turn	O
-	O
over	O
)	O
was	O
documented	O
by	O
measuring	O
the	O
recovery	O
of	O
TxB2	O
biosynthesis	O
after	O
aspirin	O
ingestion	O
(	O
30	O
).	O

The	O
data	O
show	O
that	O
platelets	O
with	O
intact	O
cyclo	B-GP
-	I-GP
oxygenase	I-GP
activity	O
can	O
be	O
detected	O
into	O
the	O
circulation	O
as	O
early	O
as	O
4	O
-	O
6	O
h	O
after	O
aspirin	O
ingestion	O
.	O

A	O
higher	O
than	O
normal	O
rate	O
of	O
entry	O
of	O
platelets	O
into	O
the	O
circulation	O
has	O
been	O
documented	O
in	O
diabetic	B-DS
angiopathy	I-DS
or	O
in	O
patients	O
with	O
coronary	O
artery	O
bypass	O
(	O
31	O
).	O

Indeed	O
,	O
schedules	O
of	O
aspirin	O
which	O
may	O
suffice	O
in	O
normal	O
subjects	O
are	O
not	O
effective	O
in	O
patients	O
with	O
diabetic	B-DS
angiopathy	I-DS
,	O
presumably	O
because	O
these	O
patients	O
have	O
a	O
high	O
rate	O
of	O
entry	O
of	O
new	O
platelets	O
into	O
the	O
circulation	O
(	O
27	O
).	O

A	O
long	O
-	O
lasting	O
suppression	O
of	O
thromboxane	O
biosynthesis	O
may	O
be	O
achieved	O
by	O
repeated	O
low	O
-	O
dose	O
administrations	O
or	O
by	O
slow	O
-	O
release	O
preparations	O
of	O
aspirin	O
.	O

The	O
relevance	O
of	O
an	O
accelerated	O
platelet	O
turn	O
-	O
over	O
as	O
to	O
‘	O
aspirin	O
resistance	O
’	O
has	O
been	O
confirmed	O
in	O
a	O
series	O
of	O
clinical	O
settings	O
(	O
32	O
,	O
33	O
).	O

Attempts	O
to	O
improve	O
the	O
efficacy	O
of	O
aspirin	O
by	O
using	O
larger	O
doses	O
have	O
been	O
associated	O
with	O
contrasting	O
results	O
(	O
34	O
).	O

Moreover	O
,	O
a	O
significant	O
higher	O
bleeding	O
risk	O
(	O
mainly	O
gastrointestinal	O
)	O
may	O
occur	O
with	O
higher	O
aspirin	O
doses	O
.	O

Thus	O
,	O
increasing	O
the	O
dose	O
of	O
aspirin	O
would	O
expose	O
the	O
patient	O
to	O
a	O
doubtful	O
clinical	O
advantage	O
(	O
35	O
).	O

Overcoming	O
limitations	O
of	O
clopidogrel	O

Changing	O
doses	O
of	O
clopidogrel	O

In	O
spite	O
of	O
the	O
greater	O
antithrombotic	O
efficacy	O
of	O
higher	O
doses	O
of	O
clopidogrel	O
,	O
thrombotic	O
events	O
still	O
occur	O
in	O
4	O
.	O
2	O
%	O
of	O
patients	O
(	O
36	O
).	O

Whereas	O
a	O
vasodilator	B-GP
-	I-GP
stimulated	I-GP
phosphoprotein	I-GP
(	O
VASP	B-GP
)-	O
tailored	O
clopidogrel	O
loading	O
dose	O
has	O
been	O
found	O
to	O
improve	O
the	O
clinical	O
outcome	O
(	O
37	O
)	O
and	O
to	O
reduce	O
the	O
rate	O
of	O
early	O
stent	O
thrombosis	O
after	O
PCI	O
(	O
38	O
),	O
the	O
GRAVITAS	O
trial	O
has	O
been	O
designed	O
to	O
evaluate	O
only	O
the	O
efficacy	O
and	O
safety	O
of	O
VASP	B-GP
-	O
tailored	O
clopidogrel	O
-	O
maintaining	O
regimens	O
(	O
39	O
).	O

Early	O
results	O
of	O
the	O
study	O
indicate	O
that	O
,	O
compared	O
with	O
standard	O
-	O
dose	O
,	O
high	O
-	O
dose	O
clopidogrel	O
only	O
achieved	O
a	O
modest	O
pharmacodynamic	O
effect	O
in	O
PCI	O
patients	O
with	O
high	O
residual	O
platelet	O
activity	O
.	O

Moreover	O
,	O
6	O
-	O
month	O
higher	O
-	O
dose	O
clopidogrel	O
did	O
not	O
reduce	O
the	O
rate	O
of	O
cardiovascular	O
death	O
,	O
non	O
-	O
fatal	O
MI	O
,	O
or	O
stent	O
thrombosis	O
,	O
nor	O
did	O
it	O
increase	O
severe	O
or	O
moderate	O
bleeding	O
.	O

Thus	O
the	O
GRAVITAS	O
study	O
does	O
not	O
support	O
a	O
treatment	O
strategy	O
of	O
high	O
clopidogrel	O
dose	O
in	O
PCI	O
patients	O
with	O
high	O
residual	O
activity	O
,	O
identified	O
by	O
a	O
single	O
platelet	O
function	O
test	O
.	O

Further	O
strategies	O
have	O
been	O
evaluated	O
to	O
overcome	O
clopidogrel	O
limitations	O
.	O
Ω	O
-	O
3	O
Ethyl	O
esters	O
(	O
1	O
g	O
/	O
day	O
for	O
1	O
month	O
)	O
added	O
to	O
standard	O
dual	O
antiplatelet	O
therapy	O
significantly	O
lowered	O
maximal	O
platelet	O
aggregation	O
in	O
response	O
to	O
ADP	O
and	O
VASP	B-GP
phosphorylation	O
as	O
well	O
(	O
40	O
).	O

Cilostazol	O
,	O
selectively	O
targeting	O
phosphodiesterase	B-GP
type	I-GP
3	I-GP
(	O
PDE3	B-GP
)	O
and	O
,	O
then	O
,	O
determining	O
intracellular	O
cAMP	O
accumulation	O
,	O
inhibits	O
platelet	O
aggregation	O
(	O
41	O
).	O

In	O
diabetic	O
patients	O
on	O
standard	O
dual	O
antiplatelet	O
therapy	O
,	O
adjunctive	O
treatment	O
with	O
cilostazol	O
enhances	O
inhibition	O
of	O
platelet	O
P2Y12	B-GP
signaling	O
(	O
42	O
).	O

A	O
Cochrane	O
review	O
(	O
43	O
),	O
in	O
which	O
two	O
randomized	O
studies	O
on	O
stroke	B-DS
prevention	O
were	O
summarized	O
,	O
documented	O
that	O
,	O
compared	O
with	O
aspirin	O
,	O
cilostazol	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
risk	O
of	O
vascular	O
events	O
(	O
6	O
.	O
77	O
%	O
versus	O
9	O
.	O
39	O
%;	O
RR	O
0	O
.	O
72	O
;	O
95	O
%	O
CI	O
0	O
.	O
57	O
-	O
0	O
.	O
91	O
,	O
composite	O
outcome	O
),	O
and	O
with	O
a	O
lower	O
risk	O
of	O
hemorrhagic	B-DS
stroke	I-DS
(	O
0	O
.	O
53	O
%	O
versus	O
2	O
.	O
01	O
%;	O
RR	O
0	O
.	O
26	O
;	O
95	O
%	O
CI	O
0	O
.	O
13	O
-	O
0	O
.	O
55	O
).	O

In	O
terms	O
of	O
outcome	O
of	O
safety	O
,	O
cilostazol	O
was	O
associated	O
with	O
significantly	O
fewer	O
adverse	O
events	O
(	O
8	O
.	O
22	O
%	O
versus	O
4	O
.	O
95	O
%;	O
RR	O
1	O
.	O
66	O
;	O
95	O
%	O
CI	O
1	O
.	O
51	O
-	O
1	O
.	O
83	O
)	O
than	O
aspirin	O
.	O

In	O
the	O
SILOAM	O
phase	O
IV	O
study	O
(	O
Clini	O
-	O
calTrials	O
.	O
gov	O
Identifier	O
:	O
NCT01261832	O
),	O
a	O
triple	O
antiplatelet	O
therapy	O
(	O
cilostazol	O
plus	O
aspirin	O
and	O
clopidogrel	O
)	O
is	O
compared	O
(	O
at	O
1	O
month	O
and	O
at	O
6	O
months	O
)	O
with	O
the	O
standard	O
dual	O
antiplatelet	O
treatment	O
(	O
ASA	O
and	O
clopidogrel	O
)	O
in	O
951	O
ACS	B-DS
subjects	O
(	O
expected	O
number	O
)	O
undergoing	O
PCI	O
and	O
drug	O
eluting	O
-	O
stent	O
implantation	O
.	O

The	O
primary	O
efficacy	O
end	O
-	O
point	O
is	O
the	O
occurrence	O
of	O
major	O
cardiovascular	O
and	O
cerebrovascular	O
events	O
(	O
total	O
death	O
,	O
non	O
-	O
fatal	O
myocardial	B-DS
infarction	I-DS
,	O
repeat	O
revascularization	O
,	O
stroke	B-DS
).	O

The	O
end	O
of	O
the	O
study	O
is	O
expected	O
by	O
January	O
2013	O
.	O

Exploring	O
newer	O
antiplatelet	O
strategies	O
(	O
Table	O
II	O
)	O

Prasugrel	O

Prasugrel	O
,	O
a	O
prodrug	O
of	O
the	O
thienopyridine	O
family	O
,	O
after	O
a	O
rapid	O
one	O
-	O
step	O
conversion	O
into	O
a	O
highly	O
bioavailable	O
metabolite	O
,	O
causes	O
an	O
irreversible	O
block	O
of	O
the	O
P2Y12	B-GP
ADP	B-GP
receptor	I-GP
.	O

Because	O
of	O
a	O
distinct	O
chemical	O
structure	O
,	O
the	O
conversion	O
to	O
its	O
active	O
metabolite	O
is	O
less	O
dependent	O
on	O
specific	O
cytochrome	B-GP
P450	I-GP
enzymes	O
than	O
that	O
of	O
other	O
thienopyridines	O
(	O
44	O
).	O

A	O
phase	O
I	O
study	O
(	O
45	O
)	O
evaluated	O
the	O
inhibition	O
of	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
by	O
prasugrel	O
(	O
60	O
mg	O
loading	O
and	O
10	O
mg	O
repeated	O
doses	O
)	O
as	O
compared	O
to	O
clopidogrel	O
(	O
300	O
mg	O
loading	O
dose	O
and	O
75	O
mg	O
repeated	O
doses	O
).	O

In	O
platelets	O
exposed	O
to	O
ADP	O
,	O
inhibition	O
of	O
the	O
aggregation	O
and	O
the	O
onset	O
of	O
the	O
antiplatelet	O
effect	O
were	O
higher	O
for	O
prasugrel	O
than	O
for	O
clopidogrel	O
(	O
maximal	O
inhibition	O
achieved	O
30	O
-	O
60	O
min	O
and	O
4	O
-	O
6	O
hours	O
after	O
prasugrel	O
and	O
clopidogrel	O
,	O
respectively	O
).	O

Of	O
interest	O
,	O
the	O
number	O
of	O
‘	O
non	O
-	O
responders	O
’	O
was	O
significantly	O
lower	O
with	O
a	O
60	O
-	O
mg	O
loading	O
dose	O
of	O
prasugrel	O
than	O
with	O
a	O
300	O
-	O
mg	O
loading	O
dose	O
of	O
clopidogrel	O
(	O
0	O
%	O
versus	O
42	O
%).	O

Molecular	O
targets	O
of	O
newer	O
and	O
emerging	O
antiplatelet	O
therapies	O
.	O

Drug	O

Mechanism	O

Comment	O

Prasugrel	O

P2Y12	B-GP
receptor	I-GP
inhibition	O

Irreversible	O
inhibition	O
;	O
orally	O
active	O

Cangrelor	O

Adenosine	O
triphosphate	O
analog	O
with	O
a	O
high	O
affinity	O
for	O
the	O
P2Y12	B-GP
receptor	I-GP

Reversible	O
inhibition	O
;	O
intravenous	O

Ticagrelor	O

P2Y12	B-GP
and	O
(	O
partly	O
)	O
P2Y1	B-GP
receptor	I-GP
inhibition	O

Reversible	O
inhibition	O
;	O
orally	O
active	O

Elinogrel	O

P2Y12	B-GP
receptor	I-GP
inhibition	O

Reversible	O
;	O
oral	O
and	O
intravenous	O

Vorapaxar	O
(	O
E530348	O
)	O

PAR	B-GP
-	I-GP
1	I-GP
inhibitor	O

No	O
effect	O
on	O
thrombin	B-GP
-	O
induced	O
fibrin	B-GP
production	O
,	O
orally	O
active	O

Atopaxar	O
(	O
E5555	O
)	O

Low	O
-	O
molecular	O
-	O
weight	O
PAR	B-GP
-	I-GP
1	I-GP
inhibitor	O

Inhibition	O
of	O
expression	O
of	O
the	O
inflammatory	O
markers	O
(	O
sCD40L	B-GP
and	O
interleukin	B-GP
6	I-GP
and	O
the	O
expression	O
of	O
P	B-GP
-	I-GP
selectin	I-GP
),	O
orally	O
active	O

Sarpogrelate	O

Selective	O
inhibitor	O
of	O
serotonin	O
(	O
5HT	B-GP
-	I-GP
2A	I-GP
)	O
platelet	B-GP
receptors	I-GP

Orally	O
active	O

DZ	O
-	O
697b	O

Inhibits	O
collagen	B-GP
and	O
ristocetin	O
-	O
mediated	O
platelet	O
adhesion	O
and	O
aggregation	O

Orally	O
active	O

Gas6	B-GP
(	O
growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
gene	I-GP
6	I-GP
)	O

Vitamin	B-GP
K	I-GP
-	I-GP
dependent	I-GP
protein	I-GP
;	O
a	O
polyclonal	O
anti	O
-	O
Gas6	B-GP
antibody	O
lowers	O
platelet	O
thromboembolism	B-DS
induced	O
by	O
the	O
intravenous	O
injection	O
of	O
collagen	B-GP
plus	O
epinephrine	O
and	O
aggregation	O
by	O
ADP	O

Stored	O
in	O
platelet	O
a	O
granules	O
,	O
released	O
upon	O
activation	O
.	O

Through	O
its	O
carboxy	O
-	O
terminal	O
domains	O
it	O
interacts	O
with	O
the	O
membrane	O
receptor	B-GP
tyrosine	I-GP
kinases	I-GP
(	O
RTKs	B-GP
)	O
of	O
the	O
TAM	B-GP
family	O
(	O
Tyro3	B-GP
,	O
Axl	B-GP
,	O
MerTK	B-GP
);	O
through	O
its	O
vitamin	B-GP
K	I-GP
-	I-GP
dependent	I-GP
Gla	I-GP
module	O
it	O
interacts	O
with	O
phosphatidylserine	O
-	O
containing	O
membranes	O

Matrix	B-GP
metalloproteinases	I-GP
(	O
MMPs	B-GP
)	O

By	O
potentiating	O
PI3K	B-GP
activation	O
,	O
MMP	B-GP
-	I-GP
2	I-GP
amplifies	O
platelet	O
aggregation	O
regardless	O
of	O
the	O
presence	O
of	O
aspirin	O
and	O
of	O
P2Y12	B-GP
receptor	I-GP
antagonists	O

Involved	O
in	O
tissue	O
remodeling	O
and	O
in	O
the	O
progression	O
of	O
atherosclerosis	B-DS
,	O
MMP	B-GP
-	I-GP
2	I-GP
is	O
present	O
in	O
platelet	O
cytosol	O
and	O
released	O
upon	O
aggregation	O

CD40	B-GP
ligand	I-GP
(	O
CD40L	B-GP
;	O
CD	B-GP
154	I-GP
)	O

On	O
activated	O
platelets	O
an	O
exodomain	O
(	O
soluble	O
CD40	B-GP
ligand	I-GP
,	O
sCD40L	B-GP
)	O
is	O
released	O
and	O
binds	O
to	O
αIIbβ3	B-GP
integrin	I-GP
,	O
thus	O
promoting	O
thrombus	O
stabilization	O
and	O
blunting	O
platelet	O
reactivity	O

Transmembrane	B-GP
protein	I-GP
expressed	O
on	O
the	O
surface	O
of	O
activated	O
platelets	O
.	O

Shedding	O
of	O
sCD40L	B-GP
from	O
the	O
surface	O
of	O
activated	O
platelets	O
can	O
be	O
prevented	O
by	O
an	O
anti	O
-	O
CD40L	B-GP
antibody	O
(	O
G28	B-GP
-	I-GP
5	I-GP
)	O

A	O
phase	O
II	O
dose	O
-	O
ranging	O
trial	O
,	O
the	O
JUMBO	O
-	O
TIMI	O
26	O
(	O
46	O
),	O
compared	O
clopidogrel	O
and	O
prasugrel	O
regimens	O
in	O
900	O
patients	O
undergoing	O
elective	O
or	O
urgent	O
PCI	O
plus	O
stenting	O
.	O

Patients	O
were	O
randomized	O
to	O
one	O
of	O
three	O
combinations	O
of	O
prasugrel	O
loading	O
and	O
maintenance	O
doses	O
:	O
40	O
mg	O
and	O
7	O
.	O
5	O
mg	O
/	O
d	O
,	O
60	O
mg	O
and	O
10	O
mg	O
/	O
d	O
,	O
and	O
60	O
mg	O
and	O
15	O
mg	O
/	O
d	O
,	O
or	O
to	O
the	O
standard	O
clopidogrel	O
regimen	O
(	O
300	O
mg	O
and	O
75	O
mg	O
/	O
d	O
).	O

While	O
the	O
thrombolysis	O
in	O
myocardial	B-DS
infarction	I-DS
(	O
TIMI	O
)	O
major	O
bleeding	O
was	O
similar	O
between	O
prasugrel	O
and	O
clopidogrel	O
groups	O
,	O
subjects	O
receiving	O
prasugrel	O
showed	O
a	O
lower	O
incidence	O
of	O
the	O
composite	O
end	O
-	O
point	O
of	O
30	O
-	O
day	O
major	O
adverse	O
cardiac	O
events	O
.	O

Likewise	O
,	O
significantly	O
lower	O
rates	O
of	O
coronary	O
target	O
vessel	O
thrombosis	O
were	O
seen	O
in	O
prasugrel	O
-	O
treated	O
patients	O
.	O

The	O
PRINCIPLE	O
-	O
TIMI	O
44	O
(	O
47	O
)	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
two	O
-	O
phase	O
cross	O
-	O
over	O
trial	O
of	O
prasugrel	O
compared	O
with	O
high	O
-	O
dose	O
clopidogrel	O
in	O
201	O
patients	O
undergoing	O
a	O
planned	O
PCI	O
.	O

In	O
the	O
first	O
phase	O
,	O
a	O
60	O
-	O
mg	O
prasugrel	O
loading	O
dose	O
was	O
compared	O
with	O
a	O
600	O
-	O
mg	O
loading	O
dose	O
of	O
clopidogrel	O
.	O

After	O
the	O
loading	O
dose	O
,	O
the	O
subjects	O
received	O
prasugrel	O
10	O
mg	O
or	O
clopidogrel	O
150	O
mg	O
for	O
14	O
days	O
,	O
and	O
then	O
they	O
were	O
crossed	O
over	O
to	O
the	O
alternative	O
treatment	O
for	O
an	O
additional	O
14	O
days	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
at	O
6	O
hours	O
following	O
20	O
μmol	O
/	O
L	O
ADP	O
.	O

After	O
the	O
loading	O
dose	O
,	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
at	O
6	O
hours	O
was	O
significantly	O
greater	O
in	O
the	O
patients	O
receiving	O
prasugrel	O
than	O
in	O
those	O
on	O
clopidogrel	O
.	O

In	O
addition	O
,	O
patients	O
on	O
prasugrel	O
showed	O
more	O
consistent	O
levels	O
of	O
platelet	O
inhibition	O
,	O
a	O
lower	O
interindividual	O
variability	O
,	O
and	O
a	O
reduced	O
incidence	O
of	O
low	O
response	O
as	O
compared	O
to	O
those	O
on	O
clopidogrel	O
.	O

The	O
same	O
figures	O
were	O
confirmed	O
after	O
14	O
days	O
of	O
maintenance	O
therapy	O
.	O

Thus	O
,	O
both	O
the	O
60	O
mg	O
loading	O
dose	O
and	O
the	O
maintenance	O
dose	O
of	O
10	O
mg	O
of	O
prasugrel	O
were	O
superior	O
to	O
clopidogrel	O
regimen	O
in	O
inhibiting	O
P2Y12	B-GP
-	O
dependent	O
platelet	O
aggregation	O
.	O

As	O
to	O
safety	O
findings	O
,	O
no	O
TIMI	O
major	O
bleeding	O
event	O
occurred	O
after	O
the	O
loading	O
dose	O
in	O
either	O
group	O
,	O
whereas	O
two	O
subjects	O
(	O
2	O
.	O
0	O
%)	O
in	O
the	O
prasugrel	O
group	O
and	O
no	O
subject	O
in	O
the	O
clopidogrel	O
group	O
experienced	O
a	O
TIMI	O
minor	O
bleeding	O
episode	O
before	O
the	O
cross	O
-	O
over	O
.	O

The	O
TRITON	O
-	O
TIMI	O
38	O
(	O
48	O
)	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
multinational	O
phase	O
III	O
trial	O
comparing	O
the	O
efficacy	O
and	O
safety	O
of	O
prasugrel	O
and	O
clopidogrel	O
in	O
13	O
,	O
608	O
subjects	O
with	O
ACS	B-DS
undergoing	O
PCI	O
and	O
coronary	O
stenting	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
prasugrel	O
(	O
60	O
-	O
mg	O
loading	O
dose	O
followed	O
by	O
a	O
10	O
-	O
mg	O
/	O
day	O
maintenance	O
dose	O
)	O
or	O
clopidogrel	O
(	O
300	O
-	O
mg	O
loading	O
dose	O
followed	O
by	O
a	O
75	O
-	O
mg	O
/	O
day	O
maintenance	O
dose	O
)	O
for	O
a	O
mean	O
of	O
14	O
.	O
5	O
months	O
.	O

The	O
primary	O
efficacy	O
end	O
-	O
point	O
(	O
death	O
from	O
CV	O
causes	O
,	O
non	O
-	O
fatal	O
MI	O
,	O
non	O
-	O
fatal	O
stroke	B-DS
)	O
occurred	O
in	O
643	O
patients	O
(	O
9	O
.	O
9	O
%)	O
receiving	O
prasugrel	O
and	O
in	O
781	O
patients	O
(	O
12	O
.	O
1	O
%)	O
receiving	O
clopidogrel	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
0	O
.	O
81	O
;	O
95	O
%	O
CI	O
0	O
.	O
73	O
-	O
0	O
.	O
90	O
;	O
P	O
=	O
0	O
.	O
001	O
).	O

An	O
early	O
significant	O
difference	O
in	O
the	O
primary	O
end	O
-	O
point	O
was	O
also	O
documented	O
at	O
the	O
3	O
-	O
day	O
pre	O
-	O
specified	O
time	O
point	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
more	O
rapid	O
onset	O
of	O
the	O
antiplatelet	O
activity	O
of	O
prasugrel	O
(	O
43	O
).	O

Such	O
difference	O
was	O
maintained	O
from	O
the	O
third	O
day	O
to	O
the	O
end	O
of	O
the	O
study	O
.	O

The	O
difference	O
in	O
the	O
primary	O
end	O
-	O
point	O
was	O
found	O
both	O
among	O
patients	O
with	O
unstable	B-DS
angina	I-DS
and	O
non	O
-	O
STEMI	O
and	O
STEMI	O
subjects	O
,	O
the	O
reduction	O
in	O
AMI	B-DS
being	O
the	O
major	O
determinant	O
of	O
such	O
difference	O
.	O

In	O
addition	O
,	O
regardless	O
of	O
the	O
type	O
of	O
stent	O
,	O
a	O
significant	O
52	O
%	O
reduction	O
of	O
stent	O
thrombosis	O
was	O
found	O
in	O
the	O
prasugrel	O
group	O
(	O
49	O
).	O

Efficacy	O
and	O
safety	O
of	O
newer	O
antiplatelet	O
drugs	O
.	O

Results	O
from	O
phase	O
III	O
studies	O
.	O

Study	O
(	O
ref	O
)	O

TRITON	O
-	O
TIMI	O
38	O
(	O
48	O
),	O
13	O
,	O
608	O
subjects	O
:	O

Study	O
design	O

Prasugrel	O
(	O
60	O
-	O
mg	O
loading	O
dose	O
(	O
LD	O
)	O
10	O
-	O
mg	O
maintenance	O
dose	O
(	O
MD	O
)	O
versus	O
Clopidogrel	O
(	O
300	O
mg	O
LD	O
75	O
mg	O
MD	O
)	O

Efficacy	O
end	O
-	O
point	O

9	O
.	O
9	O
%	O
versus	O
12	O
.	O
1	O
%;	O
P	O
=	O
0	O
.	O
001	O

Safety	O
end	O
-	O
point	O

2	O
.	O
4	O
%	O
versus	O
1	O
.	O
8	O
%;	O
P	O
=	O
0	O
.	O
03	O

CHAMPION	O
-	O
PCI	O
(	O
52	O
),	O
8	O
,	O
887	O
subjects	O
:	O

Study	O
design	O

Cangrelor	O
(	O
bolus	O
30	O
μg	O
/	O
kg	O
+	O
infusion	O
4	O
μg	O
/	O
kg	O
/	O
min	O
)	O
+	O
Clopidogrel	O
(	O
600	O
mg	O
LD	O
)	O
versus	O
Placebo	O
+	O
Clopidogrel	O
(	O
600	O
mg	O
LD	O
)	O

Efficacy	O
end	O
-	O
point	O

7	O
.	O
5	O
%	O
versus	O
7	O
.	O
9	O
%;	O
P	O
=	O
0	O
.	O
59	O

Safety	O
end	O
-	O
point	O

0	O
.	O
4	O
%	O
versus	O
0	O
.	O
3	O
%;	O
P	O
=	O
0	O
.	O
39	O

CHAMPION	O
-	O
PLATFORM	O
(	O
53	O
),	O
2	O
,	O
654	O
subjects	O
:	O

Study	O
design	O

Cangrelor	O
(	O
bolus	O
30	O
μg	O
/	O
kg	O
or	O
4	O
μg	O
/	O
kg	O
/	O
min	O
infusion	O
for	O
a	O
2	O
h	O
)	O
+	O
Clopidogrel	O
(	O
600	O
mg	O
LD	O
)	O
versus	O
Placebo	O
+	O
Clopidogrel	O
(	O
600	O
mg	O
LD	O
)	O

Efficacy	O
end	O
-	O
point	O

7	O
.	O
0	O
%	O
versus	O
8	O
.	O
0	O
%;	O
P	O
=	O
0	O
.	O
17	O

Safety	O
end	O
-	O
point	O

3	O
.	O
5	O
%	O
versus	O
5	O
.	O
5	O
%;	O
P	O
<	O
0	O
.	O
001	O

The	O
PLATO	O
trial	O
(	O
53	O
),	O
18	O
,	O
624	O
subjects	O
:	O

Study	O
design	O

Ticagrelor	O
(	O
180	O
mg	O
LD	O
+	O
90	O
mg	O
twice	O
a	O
day	O
MD	O
)	O
or	O
Clopidogrel	O
(	O
300	O
-	O
600	O
mg	O
LD	O
+	O
75	O
mg	O
MD	O
)	O

Efficacy	O
end	O
-	O
point	O

9	O
.	O
8	O
%	O
versus	O
11	O
.	O
7	O
%;	O
P	O
=	O
0	O
.	O
001	O

Safety	O
end	O
-	O
point	O

11	O
.	O
6	O
%	O
versus	O
11	O
.	O
2	O
%;	O
P	O
=	O
0	O
.	O
46	O

Efficacy	O
end	O
-	O
point	O
:	O
CV	O
death	O
/	O
non	O
-	O
fatal	O
Ml	O
/	O
non	O
-	O
fatal	O
stroke	B-DS
.	O

Safety	O
end	O
-	O
point	O
:	O
major	O
bleeding	O
.	O

Vis	O
-	O
à	O
-	O
vis	O
a	O
2	O
.	O
2	O
%	O
reduction	O
in	O
fatal	O
and	O
non	O
-	O
fatal	O
ischemic	O
events	O
,	O
both	O
TIMI	O
major	O
and	O
minor	O
bleeding	O
episodes	O
were	O
1	O
.	O
2	O
%	O
more	O
frequent	O
with	O
prasugrel	O
than	O
with	O
clopidogrel	O
.	O

The	O
TIMI	O
major	O
bleeding	O
was	O
observed	O
in	O
2	O
.	O
4	O
%	O
of	O
subjects	O
in	O
the	O
prasugrel	O
group	O
and	O
in	O
1	O
.	O
8	O
%	O
in	O
the	O
clopidogrel	O
group	O
.	O

The	O
rate	O
of	O
life	O
-	O
threatening	O
bleeding	O
(	O
1	O
.	O
4	O
%	O
versus	O
0	O
.	O
9	O
%;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
of	O
fatal	O
bleeding	O
(	O
0	O
.	O
4	O
%	O
versus	O
0	O
.	O
1	O
%;	O
P	O
=	O
0	O
.	O
002	O
)	O
was	O
greater	O
in	O
the	O
prasugrel	O
group	O
than	O
in	O
the	O
clopidogrel	O
group	O
,	O
with	O
maximal	O
bleeding	O
risk	O
in	O
patients	O
with	O
a	O
history	O
of	O
stroke	B-DS
/	O
TIA	O
(	O
in	O
whom	O
this	O
drug	O
should	O
be	O
avoided	O
,	O
being	O
associated	O
with	O
increased	O
intracranial	B-DS
hemorrhage	I-DS
),	O
in	O
elderly	O
patients	O
(	O
aged	O
≥	O
75	O
years	O
)	O
and	O
in	O
those	O
with	O
a	O
body	O
-	O
weight	O
<	O
60	O
kg	O
.	O

On	O
the	O
other	O
hand	O
,	O
based	O
on	O
TIMI	O
major	O
bleedings	O
(	O
key	O
safety	O
end	O
-	O
point	O
of	O
the	O
trial	O
),	O
prasugrel	O
should	O
also	O
be	O
used	O
with	O
caution	O
in	O
candidates	O
to	O
Coronary	O
Artery	O
Bypass	O
Graft	O
(	O
CABG	O
),	O
>	O
50	O
%	O
of	O
total	O
bleedings	O
being	O
reported	O
in	O
this	O
setting	O
.	O

Together	O
,	O
in	O
a	O
risk	O
/	O
benefit	O
analysis	O
,	O
prasugrel	O
was	O
13	O
%	O
better	O
than	O
clopidogrel	O
(	O
HR	O
0	O
.	O
87	O
;	O
95	O
%	O
CI	O
0	O
.	O
79	O
-	O
0	O
.	O
95	O
;	O
P	O
=	O
0	O
.	O
004	O
),	O
maximal	O
clinical	O
benefit	O
being	O
found	O
in	O
patients	O
with	O
diabetes	B-DS
,	O
with	O
coronary	O
stents	O
,	O
or	O
with	O
recurrent	O
events	O
(	O
RRR	O
30	O
%).	O

Whether	O
prasugrel	O
is	O
safer	O
and	O
better	O
than	O
clopidogrel	O
in	O
reducing	O
the	O
risk	O
of	O
cardiovascular	O
death	O
,	O
MI	O
,	O
or	O
stroke	B-DS
,	O
in	O
patients	O
with	O
ACS	B-DS
who	O
are	O
medically	O
managed	O
,	O
and	O
in	O
whom	O
no	O
revascularization	O
is	O
planned	O
,	O
will	O
be	O
evaluated	O
in	O
the	O
TRILOGY	O
ACS	B-DS
study	O
,	O
a	O
phase	O
III	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
including	O
approximately	O
10	O
,	O
000	O
patients	O
(	O
50	O
).	O

Cangrelor	O

Cangrelor	O
,	O
an	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
analog	O
with	O
a	O
high	O
affinity	O
for	O
the	O
P2Y12	B-GP
receptor	I-GP
(	O
35	O
),	O
does	O
not	O
need	O
conversion	O
,	O
being	O
immediately	O
active	O
following	O
infusion	O
(	O
half	O
-	O
life	O
of	O
3	O
-	O
6	O
min	O
).	O

In	O
the	O
STEP	O
-	O
AMI	B-DS
trial	O
,	O
92	O
ACS	B-DS
patients	O
(	O
51	O
)	O
treated	O
with	O
aspirin	O
and	O
heparin	O
were	O
randomized	O
to	O
receive	O
cangrelor	O
(	O
280	O
μg	O
/	O
kg	O
/	O
min	O
)	O
alone	O
,	O
full	O
-	O
dose	O
tissue	B-GP
plasminogen	I-GP
activator	I-GP
(	O
t	B-GP
-	I-GP
PA	I-GP
)	O
alone	O
,	O
or	O
cangrelor	O
(	O
35	O
,	O
140	O
,	O
or	O
280	O
μg	O
/	O
kg	O
/	O
min	O
)	O
in	O
combination	O
with	O
half	O
-	O
dose	O
t	B-GP
-	I-GP
PA	I-GP
.	O

A	O
60	O
-	O
min	O
coronary	O
patency	O
similar	O
to	O
that	O
of	O
full	O
-	O
dose	O
t	B-GP
-	I-GP
PA	I-GP
alone	O
and	O
a	O
greater	O
patency	O
than	O
with	O
cangrelor	O
alone	O
was	O
found	O
in	O
patients	O
receiving	O
the	O
combination	O
of	O
cangrelor	O
and	O
half	O
-	O
dose	O
t	B-GP
-	I-GP
PA	I-GP
.	O

Although	O
in	O
two	O
randomized	O
controlled	O
clinical	O
phase	O
III	O
trials	O
on	O
ACS	B-DS
patients	O
requiring	O
PCI	O
(	O
CHAMPION	O
PCI	O
,	O
CHAMPION	O
PLATFORM	O
)	O
(	O
52	O
,	O
53	O
),	O
cangrelor	O
did	O
not	O
show	O
superiority	O
over	O
clopidogrel	O
,	O
this	O
drug	O
is	O
currently	O
investigated	O
as	O
a	O
bridge	O
to	O
CABG	O
surgery	O
(	O
ClinicalTrials	O
.	O
gov	O
Identifier	O
:	O
NCT00767507	O
).	O

Ticagrelor	O

Ticagrelor	O
,	O
an	O
orally	O
active	O
cyclopentyl	O
-	O
triazolo	O
-	O
pyrimidine	O
,	O
binds	O
to	O
domains	O
of	O
the	O
P2Y12	B-GP
receptor	I-GP
other	O
than	O
those	O
recognized	O
by	O
ADP	O
(	O
the	O
1	O
,	O
2	O
,	O
and	O
7	O
transmembrane	O
domains	O
,	O
the	O
extracellular	O
loop	O
2	O
,	O
and	O
the	O
N	O
-	O
terminal	O
domain	O
),	O
determining	O
a	O
potent	O
and	O
rapid	O
non	O
-	O
persistent	O
receptor	O
conformational	O
change	O
.	O

After	O
the	O
occupancy	O
of	O
P2Y12	B-GP
,	O
ADP	O
-	O
catalyzed	O
conversion	O
of	O
cAMP	O
from	O
ATP	O
,	O
dephosphorylation	O
of	O
phosphorylated	O
VASP	B-GP
,	O
and	O
activation	O
of	O
phosphoinositide	B-GP
3	I-GP
-	I-GP
kinase	I-GP
are	O
blocked	O
.	O

The	O
net	O
result	O
is	O
a	O
reduced	O
exposure	O
of	O
fibrinogen	B-GP
-	O
binding	O
sites	O
on	O
the	O
αIIbβ3	B-GP
integrin	I-GP
receptor	I-GP
and	O
,	O
in	O
turn	O
,	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
.	O

Inhibition	O
of	O
ADP	O
-	O
mediated	O
constriction	O
of	O
vascular	O
smooth	O
muscle	O
and	O
enhancement	O
of	O
adenosine	O
-	O
induced	O
coronary	O
blood	O
-	O
flow	O
are	O
also	O
reported	O
.	O

After	O
oral	O
administration	O
,	O
ticagrelor	O
is	O
rapidly	O
absorbed	O
and	O
does	O
not	O
require	O
hepatic	O
biotransformation	O
to	O
be	O
pharmacologically	O
active	O
.	O

However	O
,	O
ticagrelor	O
is	O
also	O
metabolized	O
to	O
an	O
equipotent	O
,	O
active	O
metabolite	O
(	O
AR	O
-	O
C124910XX	O
)	O
by	O
CYP3A4	B-GP
enzymes	O
.	O

Being	O
both	O
ticagrelor	O
and	O
AR	O
-	O
C124910XX	O
-	O
excreted	O
by	O
the	O
intestinal	O
route	O
,	O
no	O
dose	O
adjustment	O
is	O
needed	O
in	O
kidney	B-DS
failure	I-DS
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
concomitant	O
use	O
of	O
CYP3A4	B-GP
inhibitors	O
/	O
inducers	O
as	O
well	O
as	O
a	O
significant	O
liver	B-DS
dysfunction	I-DS
may	O
be	O
of	O
concern	O
for	O
its	O
use	O
(	O
54	O
).	O

After	O
pharmacodynamic	O
evaluations	O
(	O
55	O
,	O
56	O
),	O
a	O
90	O
-	O
mg	O
twice	O
daily	O
dose	O
of	O
ticagrelor	O
has	O
been	O
chosen	O
to	O
optimize	O
its	O
efficacy	O
,	O
safety	O
,	O
and	O
tolerability	O
.	O

A	O
loading	O
dose	O
of	O
180	O
-	O
270	O
mg	O
may	O
minimize	O
intersubject	O
variability	O
as	O
to	O
initial	O
inhibition	O
in	O
platelet	O
aggregation	O
and	O
may	O
be	O
appropriate	O
in	O
ticagrelor	O
-	O
naive	O
patients	O
with	O
ACS	B-DS
or	O
in	O
preparation	O
for	O
PCI	O
.	O

In	O
174	O
subjects	O
with	O
a	O
recent	O
coronary	B-DS
artery	I-DS
disease	I-DS
receiving	O
75	O
-	O
100	O
mg	O
/	O
day	O
aspirin	O
(	O
92	O
also	O
under	O
ticagrelor	O
180	O
-	O
mg	O
load	O
and	O
90	O
mg	O
/	O
twice	O
daily	O
maintenance	O
dose	O
,	O
and	O
82	O
also	O
under	O
clopidogrel	O
600	O
-	O
mg	O
load	O
and	O
75	O
mg	O
/	O
d	O
maintenance	O
dose	O
)	O
the	O
genotyping	O
of	O
the	O
cytochrome	B-GP
P450	I-GP
(	B-GP
CYP	I-GP
)	I-GP
2C19	I-GP
(*	O
1	O
,*	O
2	O
,*	O
3	O
,*	O
4	O
,*	O
5	O
,*	O
6	O
,*	O
7	O
,*	O
8	O
,*	O
17	O
)	O
was	O
performed	O
.	O

In	O
addition	O
,	O
platelet	O
function	O
was	O
measured	O
by	O
aggregometry	O
,	O
VerifyNow	O
P2Y12	B-GP
assay	O
,	O
and	O
VASP	B-GP
assay	O
at	O
pre	O
-	O
dose	O
,	O
8	O
hours	O
post	O
-	O
loading	O
,	O
and	O
during	O
maintenance	O
.	O

There	O
was	O
no	O
significant	O
effect	O
of	O
the	O
genotype	O
on	O
platelet	O
function	O
during	O
aspirin	O
therapy	O
alone	O
.	O

On	O
the	O
other	O
hand	O
,	O
irrespective	O
of	O
the	O
2C19	O
genotype	O
,	O
of	O
the	O
metabolizer	O
status	O
,	O
and	O
of	O
the	O
assays	O
employed	O
,	O
subjects	O
on	O
ticagrelor	O
showed	O
a	O
lower	O
platelet	O
reactivity	O
than	O
did	O
those	O
on	O
clopidogrel	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

This	O
is	O
consistent	O
with	O
a	O
genotype	O
-	O
independent	O
better	O
pharmacodynamic	O
effect	O
of	O
ticagrelor	O
as	O
compared	O
to	O
clopidogrel	O
(	O
57	O
).	O

The	O
DISPERSE	O
trial	O
(	O
200	O
subjects	O
with	O
stable	O
atherosclerotic	B-DS
disease	I-DS
)	O
(	O
54	O
)	O
showed	O
ticagrelor	O
(	O
100	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.,	O
200	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.,	O
or	O
400	O
mg	O
/	O
d	O
)	O
to	O
inhibit	O
platelet	O
aggregation	O
more	O
rapidly	O
and	O
effectively	O
and	O
with	O
less	O
variability	O
than	O
clopidogrel	O
(	O
75	O
mg	O
/	O
d	O
).	O

The	O
DISPERSE	O
-	O
2	O
trial	O
(	O
58	O
)	O
(	O
990	O
NSTEMI	O
patients	O
)	O
showed	O
that	O
ticagrelor	O
,	O
added	O
to	O
standard	O
medical	O
treatment	O
,	O
has	O
a	O
safety	O
profile	O
similar	O
to	O
clopidogrel	O
with	O
a	O
better	O
profile	O
as	O
to	O
the	O
incidence	O
of	O
AMI	B-DS
,	O
silent	O
AMI	B-DS
,	O
severe	O
recurrent	O
ischemia	B-DS
,	O
stroke	B-DS
,	O
and	O
death	O
.	O

However	O
,	O
the	O
study	O
was	O
not	O
powered	O
to	O
detect	O
differences	O
in	O
efficacy	O
end	O
-	O
points	O
(	O
size	O
),	O
nor	O
was	O
the	O
duration	O
of	O
the	O
drug	O
exposure	O
appropriate	O
(	O
52	O
).	O

The	O
PLATO	O
trial	O
was	O
a	O
phase	O
III	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
study	O
that	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
ticagrelor	O
and	O
of	O
clopidogrel	O
in	O
lowering	O
the	O
risk	O
of	O
vascular	O
events	O
in	O
more	O
than	O
18	O
,	O
000	O
NSTEMI	O
or	O
STEMI	O
patients	O
(	O
59	O
).	O

Within	O
24	O
hours	O
after	O
a	O
diagnosis	O
of	O
ACS	B-DS
,	O
the	O
patients	O
were	O
randomized	O
to	O
receive	O
ticagrelor	O
90	O
mg	O
/	O
twice	O
daily	O
or	O
clopidogrel	O
75	O
mg	O
once	O
daily	O
for	O
6	O
-	O
12	O
months	O
.	O

Before	O
starting	O
the	O
maintenance	O
dose	O
,	O
each	O
subject	O
received	O
a	O
loading	O
dose	O
of	O
180	O
mg	O
ticagrelor	O
or	O
300	O
mg	O
clopidogrel	O
,	O
depending	O
on	O
the	O
group	O
of	O
randomization	O
.	O

All	O
subjects	O
received	O
concomitant	O
treatment	O
with	O
aspirin	O
75	O
-	O
100	O
mg	O
/	O
day	O
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
the	O
time	O
to	O
the	O
first	O
occurrence	O
of	O
cardiovascular	O
or	O
cerebrovascular	O
death	O
,	O
non	O
-	O
fatal	O
MI	O
,	O
or	O
non	O
-	O
fatal	O
stroke	B-DS
.	O

The	O
primary	O
safety	O
outcome	O
was	O
the	O
time	O
to	O
the	O
first	O
occurrence	O
of	O
any	O
major	O
bleeding	O
event	O
.	O

At	O
12	O
months	O
,	O
the	O
primary	O
end	O
-	O
point	O
occurred	O
in	O
9	O
.	O
8	O
%	O
of	O
patients	O
receiving	O
ticagrelor	O
as	O
compared	O
with	O
11	O
.	O
7	O
%	O
of	O
those	O
receiving	O
clopidogrel	O
(	O
HR	O
0	O
.	O
84	O
;	O
95	O
%	O
CI	O
0	O
.	O
77	O
-	O
0	O
.	O
92	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Similar	O
figures	O
were	O
achieved	O
by	O
evaluating	O
the	O
rate	O
of	O
the	O
primary	O
outcome	O
at	O
30	O
days	O
(	O
4	O
.	O
8	O
%	O
for	O
ticagrelor	O
group	O
versus	O
5	O
.	O
4	O
%	O
for	O
clopidogrel	O
group	O
;	O
P	O
=	O
0	O
.	O
045	O
).	O

The	O
rate	O
of	O
death	O
from	O
any	O
cause	O
was	O
also	O
reduced	O
with	O
ticagrelor	O
(	O
4	O
.	O
5	O
%	O
versus	O
5	O
.	O
9	O
%	O
with	O
clopidogrel	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Major	O
,	O
life	O
-	O
threatening	O
,	O
or	O
fatal	O
bleedings	O
did	O
not	O
differ	O
between	O
those	O
on	O
ticagrelor	O
and	O
on	O
clopidogrel	O
(	O
11	O
.	O
6	O
%	O
and	O
11	O
.	O
2	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
43	O
),	O
nor	O
did	O
CABG	O
-	O
related	O
major	O
bleeding	O
,	O
although	O
ticagrelor	O
patients	O
were	O
allowed	O
to	O
undergo	O
CABG	O
earlier	O
(	O
24	O
-	O
72	O
hours	O
),	O
after	O
withdrawing	O
from	O
the	O
study	O
drug	O
,	O
as	O
compared	O
to	O
those	O
on	O
clopidogrel	O
(	O
5	O
days	O
).	O

However	O
,	O
Vis	O
-	O
à	O
-	O
vis	O
fewer	O
fatal	O
bleeding	O
episodes	O
of	O
other	O
types	O
,	O
a	O
higher	O
rate	O
of	O
higher	O
major	O
bleeding	O
not	O
related	O
to	O
coronary	O
artery	O
bypass	O
grafting	O
(	O
4	O
.	O
5	O
%	O
versus	O
3	O
.	O
8	O
%;	O
P	O
=	O
0	O
.	O
03	O
),	O
including	O
fatal	O
intracranial	B-DS
bleedings	I-DS
,	O
were	O
detected	O
in	O
subjects	O
on	O
ticagrelor	O
.	O

Secondary	O
end	O
-	O
point	O
evaluation	O
showed	O
significant	O
differences	O
in	O
the	O
rates	O
of	O
myocardial	B-DS
infarction	I-DS
(	O
5	O
.	O
8	O
%	O
in	O
the	O
ticagrelor	O
group	O
versus	O
6	O
.	O
9	O
%	O
in	O
the	O
clopidogrel	O
group	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
and	O
of	O
death	O
from	O
vascular	O
causes	O
(	O
4	O
.	O
0	O
%	O
versus	O
5	O
.	O
1	O
%;	O
P	O
=	O
0	O
.	O
001	O
),	O
but	O
not	O
of	O
stroke	B-DS
(	O
1	O
.	O
5	O
%	O
versus	O
1	O
.	O
3	O
%;	O
P	O
=	O
0	O
.	O
22	O
).	O

More	O
patients	O
in	O
the	O
ticagrelor	O
group	O
discontinued	O
the	O
study	O
drug	O
due	O
to	O
adverse	O
events	O
compared	O
to	O
the	O
clopidogrel	O
group	O
(	O
7	O
.	O
4	O
%	O
versus	O
6	O
.	O
0	O
%;	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
significantly	O
higher	O
reversible	O
increase	O
in	O
serum	O
uric	O
acid	O
and	O
creatinine	O
was	O
found	O
in	O
subjects	O
receiving	O
ticagrelor	O
.	O

Dyspnea	O
,	O
nausea	O
,	O
hypotension	O
,	O
and	O
asymptomatic	O
ventricular	O
pauses	O
were	O
more	O
frequent	O
in	O
the	O
ticagrelor	O
group	O
,	O
maybe	O
because	O
of	O
an	O
adenosine	O
-	O
mediated	O
response	O
(	O
60	O
).	O

Thus	O
,	O
the	O
use	O
of	O
ticagrelor	O
should	O
be	O
evaluated	O
with	O
caution	O
in	O
patients	O
with	O
hyperuricemia	O
,	O
bradyar	O
-	O
rhythmias	O
without	O
pacemakers	O
,	O
and	O
syncope	O
and	O
in	O
those	O
at	O
high	O
risk	O
of	O
bleeding	O
(	O
e	O
.	O
g	O
.	O
elderly	O
,	O
low	O
body	O
-	O
weight	O
,	O
renal	B-DS
dysfunction	I-DS
)	O
and	O
avoided	O
in	O
patients	O
with	O
history	O
of	O
stroke	B-DS
(	O
61	O
).	O

Of	O
interest	O
,	O
in	O
the	O
ONSET	O
/	O
OFFSET	O
study	O
,	O
123	O
patients	O
with	O
stable	O
coronary	B-DS
artery	I-DS
disease	I-DS
receiving	O
aspirin	O
(	O
75	O
-	O
100	O
mg	O
/	O
d	O
)	O
received	O
on	O
top	O
ticagrelor	O
(	O
180	O
-	O
mg	O
load	O
,	O
90	O
-	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
maintenance	O
dose	O
(	O
n	O
=	O
57	O
)),	O
clopidogrel	O
(	O
600	O
-	O
mg	O
load	O
,	O
75	O
-	O
mg	O
/	O
d	O
maintenance	O
dose	O
(	O
n	O
=	O
54	O
)),	O
or	O
placebo	O
(	O
n	O
=	O
12	O
)	O
for	O
6	O
weeks	O
.	O

Ticagrelor	O
achieved	O
a	O
more	O
rapid	O
and	O
greater	O
platelet	O
inhibition	O
(	O
evaluated	O
with	O
20	O
μmol	O
/	O
L	O
ADP	O
)	O
than	O
did	O
high	O
-	O
loading	O
-	O
dose	O
clopidogrel	O
.	O

In	O
addition	O
,	O
a	O
faster	O
offset	O
occurred	O
with	O
ticagrelor	O
than	O
with	O
clopidogrel	O
(	O
4	O
-	O
72	O
-	O
hour	O
slope	O
(%	O
inhibition	O
of	O
platelet	O
aggregation	O
/	O
h	O
)	O
-	O
1	O
.	O
04	O
versus	O
-	O
0	O
.	O
48	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
62	O
).	O

To	O
evaluate	O
further	O
the	O
safety	O
and	O
efficacy	O
parameters	O
,	O
in	O
a	O
phase	O
III	O
study	O
(	O
NCT01294462	O
)	O
90	O
mg	O
/	O
twice	O
daily	O
ticagrelor	O
(	O
on	O
top	O
of	O
100	O
mg	O
aspirin	O
)	O
will	O
be	O
compared	O
to	O
75	O
mg	O
clopidogrel	O
(	O
on	O
top	O
of	O
100	O
mg	O
aspirin	O
as	O
well	O
)	O
in	O
ACS	B-DS
subjects	O
with	O
a	O
planned	O
PCI	O
.	O

The	O
safety	O
outcome	O
will	O
be	O
evaluated	O
by	O
measuring	O
the	O
time	O
to	O
first	O
occurrence	O
of	O
any	O
major	O
bleeding	O
event	O
.	O

The	O
time	O
to	O
first	O
occurrence	O
of	O
the	O
composite	O
of	O
death	O
from	O
any	O
vascular	O
cause	O
(	O
myocardial	B-DS
infarction	I-DS
and	O
stroke	B-DS
)	O
will	O
also	O
be	O
measured	O
.	O

The	O
study	O
is	O
expected	O
to	O
enroll	O
800	O
subjects	O
,	O
and	O
the	O
estimated	O
study	O
completion	O
date	O
is	O
August	O
2012	O
.	O

In	O
addition	O
,	O
a	O
randomized	O
phase	O
III	O
PEGASUS	O
trial	O
(	O
NCT01225562	O
),	O
on	O
an	O
expected	O
number	O
of	O
21	O
,	O
000	O
subjects	O
with	O
a	O
history	O
of	O
myocardial	B-DS
infarction	I-DS
,	O
will	O
evaluate	O
the	O
efficacy	O
of	O
ticagrelor	O
(	O
90	O
or	O
60	O
mg	O
/	O
twice	O
daily	O
)	O
compared	O
to	O
placebo	O
on	O
top	O
of	O
aspirin	O
(	O
100	O
mg	O
)	O
in	O
the	O
prevention	O
of	O
the	O
composite	O
end	O
-	O
point	O
of	O
cardiovascular	O
death	O
,	O
non	O
-	O
fatal	O
MI	O
,	O
or	O
non	O
-	O
fatal	O
stroke	B-DS
.	O

The	O
end	O
of	O
the	O
study	O
is	O
expected	O
by	O
February	O
2014	O
.	O

Elinogrel	O

Elinogrel	O
(	O
PRT128	O
)	O
is	O
a	O
direct	O
,	O
reversible	O
P2Y12	B-GP
inhibitor	O
available	O
in	O
both	O
oral	O
and	O
intravenous	O
formulations	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
63	O
)	O
in	O
which	O
single	O
intravenous	O
doses	O
(	O
1	O
–	O
40	O
mg	O
)	O
were	O
administered	O
,	O
elinogrel	O
yielded	O
a	O
dose	O
-	O
dependent	O
,	O
complete	O
inhibition	O
of	O
ADP	O
-	O
induced	O
aggregation	O
.	O

All	O
doses	O
of	O
elinogrel	O
were	O
well	O
tolerated	O
,	O
with	O
no	O
serious	O
adverse	O
events	O
observed	O
.	O

Sarpogrelate	O

Sarpogrelate	O
is	O
a	O
selective	O
inhibitor	O
of	O
5	B-GP
-	I-GP
HT	I-GP
platelet	I-GP
receptors	I-GP
.	O

In	O
the	O
S	O
-	O
ACCESS	O
trial	O
(	O
64	O
),	O
1	O
,	O
510	O
patients	O
with	O
recent	O
cerebral	B-DS
infarction	I-DS
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
sarpogrelate	O
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.)	O
or	O
aspirin	O
(	O
81	O
mg	O
/	O
day	O
).	O

Mean	O
follow	O
-	O
up	O
was	O
1	O
.	O
59	O
years	O
,	O
with	O
the	O
recurrence	O
of	O
a	O
cerebral	B-DS
infarction	I-DS
as	O
primary	O
efficacy	O
end	O
-	O
point	O
.	O

Clusters	O
of	O
serious	O
vascular	O
events	O
(	O
stroke	B-DS
,	O
acute	B-DS
coronary	I-DS
syndrome	I-DS
,	O
or	O
vascular	O
death	O
)	O
were	O
secondary	O
end	O
-	O
points	O
.	O

The	O
aim	O
of	O
the	O
primary	O
efficacy	O
analysis	O
was	O
the	O
non	O
-	O
inferiority	O
of	O
sarpogrelate	O
with	O
respect	O
to	O
aspirin	O
,	O
the	O
upper	O
limit	O
of	O
the	O
95	O
%	O
CI	O
of	O
the	O
hazard	O
ratio	O
for	O
the	O
recurrence	O
of	O
cerebral	B-DS
infarction	I-DS
not	O
exceeding	O
1	O
.	O
33	O
.	O

Cerebral	B-DS
infarction	I-DS
recurred	O
in	O
72	O
patients	O
in	O
the	O
sarpogrelate	O
group	O
and	O
in	O
58	O
in	O
the	O
aspirin	O
group	O
(	O
HR	O
1	O
.	O
25	O
;	O
95	O
%	O
CI	O
0	O
.	O
89	O
-	O
1	O
.	O
77	O
;	O
P	O
=	O
0	O
.	O
19	O
).	O

A	O
serious	O
vascular	O
event	O
occurred	O
in	O
90	O
and	O
in	O
85	O
patients	O
,	O
respectively	O
(	O
HR	O
1	O
.	O
07	O
;	O
95	O
%	O
CI	O
0	O
.	O
80	O
-	O
1	O
.	O
44	O
;	O
P	O
=	O
0	O
.	O
65	O
).	O

The	O
overall	O
incidence	O
of	O
bleeding	O
events	O
was	O
89	O
(	O
11	O
.	O
9	O
%)	O
and	O
131	O
(	O
17	O
.	O
3	O
%),	O
respectively	O

DZ	O
-	O
697b	O

DZ	O
-	O
697b	O
inhibits	O
collagen	B-GP
and	O
ristocetin	O
-	O
mediated	O
platelet	O
adhesion	O
and	O
aggregation	O
and	O
does	O
not	O
require	O
metabolization	O
to	O
generate	O
its	O
active	O
compound	O
(	O
65	O
).	O

The	O
antithrombotic	O
effect	O
and	O
the	O
bleeding	O
time	O
prolongation	O
of	O
three	O
DZ	O
-	O
697b	O
doses	O
were	O
compared	O
with	O
300	O
mg	O
clopidogrel	O
in	O
20	O
healthy	O
subjects	O
randomized	O
to	O
a	O
single	O
oral	O
dose	O
of	O
DZ	O
-	O
697b	O
(	O
60	O
,	O
120	O
,	O
and	O
360	O
mg	O
)	O
or	O
clopidogrel	O
(	O
300	O
mg	O
).	O

DZ	O
-	O
697b	O
(	O
120	O
mg	O
)	O
showed	O
antithrombotic	O
effects	O
comparable	O
to	O
300	O
mg	O
clopidogrel	O
,	O
with	O
significantly	O
reduced	O
bleeding	O
time	O
prolongations	O
.	O

Atopaxar	O
(	O
E5555	O
)	O

Atopaxar	O
(	O
E5555	O
)	O
is	O
a	O
small	O
molecule	O
,	O
1	O
-(	O
3	O
-	O
tert	O
-	O
butyl	O
-	O
4	O
-	O
methoxy	O
-	O
5	O
-	O
morpholinophenyl	O
)	O
-	O
2	O
-	O
(	O
5	O
,	O
6	O
-	O
diethoxy	O
-	O
7	O
-	O
fluoro	O
-	O
1	O
-	O
intino	O
-	O
1	O
,	O
3	O
-	O
dihydro	O
-	O
2H	O
-	O
isoindol	O
-	O
2yl	O
)	O
ethanone	O
hydrobromide	O
that	O
acts	O
as	O
PAR	B-GP
-	I-GP
1	I-GP
antagonist	O
.	O

In	O
healthy	O
volunteers	O
,	O
E5555	O
showed	O
antiplatelet	O
effects	O
without	O
increasing	O
bleeding	O
times	O
.	O

Two	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
II	O
clinical	O
trials	O
(	O
J	O
-	O
LANCELOT	O
)	O
(	O
66	O
)	O
have	O
assessed	O
the	O
safety	O
and	O
tolerability	O
of	O
atopaxar	O
in	O
addition	O
to	O
standard	O
therapy	O
in	O
patients	O
with	O
ACS	B-DS
or	O
high	O
-	O
risk	O
coronary	B-DS
artery	I-DS
disease	I-DS
.	O

In	O
addition	O
to	O
aspirin	O
,	O
patients	O
received	O
atopaxar	O
(	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
)	O
or	O
placebo	O
once	O
daily	O
for	O
12	O
or	O
24	O
weeks	O
.	O

All	O
atopaxar	O
doses	O
tested	O
achieved	O
a	O
significant	O
level	O
of	O
platelet	O
inhibition	O
with	O
no	O
increase	O
in	O
severe	O
bleeding	O
episodes	O
.	O

The	O
rate	O
of	O
major	O
cardiovascular	O
adverse	O
events	O
in	O
the	O
atopaxar	O
group	O
was	O
similar	O
to	O
placebo	O
(	O
ACS	B-DS
6	O
.	O
6	O
%	O
and	O
5	O
.	O
0	O
%	O
in	O
placebo	O
or	O
E5555	O
,	O
respectively	O
,	O
P	O
=	O
0	O
.	O
73	O
;	O
CAD	B-DS
4	O
.	O
5	O
%	O
placebo	O
versus	O
1	O
.	O
0	O
%	O
E5555	O
,	O
P	O
=	O
0	O
.	O
066	O
).	O

Vorapaxar	O

Vorapaxar	O
(	O
SCH	O
530348	O
)	O
is	O
an	O
orally	O
active	O
and	O
reversible	O
agent	O
belonging	O
to	O
the	O
class	O
of	O
thrombin	B-GP
receptor	I-GP
antagonists	O
(	O
TRAs	O
).	O

Vorapaxar	O
blocks	O
the	O
platelet	O
PAR	B-GP
-	I-GP
1	I-GP
receptor	I-GP
,	O
inhibiting	O
thrombin	B-GP
-	O
induced	O
activation	O
and	O
aggregation	O
of	O
platelets	O
without	O
affecting	O
thrombin	B-GP
-	O
induced	O
fibrin	B-GP
production	O
.	O

Phase	O
I	O
study	O
data	O
showed	O
a	O
significant	O
dose	O
-	O
related	O
inhibition	O
of	O
platelet	O
aggregation	O
with	O
>	O
90	O
%	O
inhibition	O
at	O
1	O
h	O
,	O
lasting	O
at	O
least	O
72	O
h	O
in	O
the	O
absence	O
of	O
significant	O
adverse	O
events	O
(	O
67	O
).	O

The	O
TRA	O
-	O
PCI	O
(	O
68	O
),	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
multicenter	O
phase	O
II	O
study	O
,	O
was	O
designed	O
to	O
assess	O
tolerability	O
and	O
safety	O
of	O
an	O
oral	O
loading	O
dose	O
of	O
vorapaxar	O
(	O
10	O
mg	O
,	O
20	O
mg	O
,	O
or	O
40	O
mg	O
)	O
in	O
patients	O
undergoing	O
coronary	O
angiography	O
with	O
planned	O
PCI	O
.	O

In	O
addition	O
to	O
the	O
standard	O
of	O
care	O
(	O
aspirin	O
±	O
clopidogrel	O
),	O
those	O
who	O
subsequently	O
underwent	O
PCI	O
received	O
an	O
oral	O
maintenance	O
dose	O
(	O
0	O
.	O
5	O
mg	O
,	O
1	O
.	O
0	O
mg	O
,	O
or	O
2	O
.	O
5	O
mg	O
/	O
day	O
)	O
of	O
vorapaxar	O
or	O
placebo	O
for	O
60	O
days	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
the	O
incidence	O
of	O
clinically	O
significant	O
major	O
or	O
minor	O
bleeding	O
according	O
to	O
theTIMI	O
scale	O
.	O

In	O
spite	O
of	O
the	O
limited	O
time	O
of	O
observation	O
(	O
60	O
days	O
)	O
versus	O
the	O
very	O
long	O
half	O
-	O
life	O
(	O
100	O
-	O
360	O
h	O
)	O
of	O
vorapaxar	O
,	O
no	O
difference	O
in	O
the	O
primary	O
end	O
-	O
point	O
of	O
major	O
or	O
minor	O
bleeding	O
has	O
been	O
found	O
(	O
2	O
%,	O
3	O
%,	O
4	O
%	O
in	O
the	O
three	O
loading	O
dose	O
groups	O
versus	O
3	O
.	O
3	O
%	O
in	O
placebo	O
group	O
;	O
P	O
=	O
0	O
.	O
57	O
).	O

Nor	O
were	O
significant	O
differences	O
in	O
major	O
cardiovascular	O
events	O
observed	O
in	O
the	O
two	O
groups	O
.	O

Platelet	O
function	O
testing	O
showed	O
a	O
very	O
potent	O
and	O
sustained	O
effect	O
with	O
the	O
40	O
-	O
mg	O
loading	O
dose	O
and	O
the	O
2	O
.	O
5	O
-	O
mg	O
maintenance	O
dose	O
.	O

In	O
a	O
subgroup	O
of	O
subjects	O
undergoing	O
coronary	O
bypass	O
surgery	O
while	O
under	O
vorapaxar	O
,	O
there	O
was	O
no	O
evidence	O
of	O
increased	O
bleeding	O
,	O
suggesting	O
that	O
PAR	B-GP
-	I-GP
1	I-GP
blockade	O
during	O
cardiopulmonary	O
bypass	O
may	O
‘	O
preserve	O
’	O
normal	O
hemostasis	O
(	O
69	O
).	O

In	O
a	O
phase	O
II	O
study	O
(	O
70	O
),	O
117	O
NSTEMI	O
patients	O
undergoing	O
non	O
-	O
urgent	O
PCI	O
have	O
been	O
randomized	O
to	O
receive	O
,	O
on	O
top	O
of	O
standard	O
dual	O
antiplatelet	O
therapy	O
(	O
aspirin	O
+	O
ticlopidine	O
)	O
and	O
heparin	O
,	O
two	O
different	O
dosages	O
of	O
vorapaxar	O
(	O
20	O
mg	O
or	O
40	O
mg	O
loading	O
dose	O
,	O
followed	O
by	O
1	O
mg	O
/	O
d	O
or	O
2	O
.	O
5	O
mg	O
/	O
d	O
maintenance	O
dose	O
)	O
or	O
placebo	O
.	O

While	O
TIMI	O
major	O
and	O
minor	O
bleedings	O
were	O
similar	O
between	O
the	O
different	O
treatment	O
arms	O
(	O
14	O
%	O
versus	O
10	O
%),	O
peri	O
-	O
procedural	O
AMI	B-DS
was	O
significantly	O
lower	O
in	O
treated	O
patients	O
(	O
16	O
.	O
9	O
%	O
versus	O
42	O
.	O
9	O
in	O
the	O
placebo	O
group	O
%;	O
P	O
=	O
0	O
.	O
013	O
).	O

Two	O
large	O
multicenter	O
,	O
international	O
,	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
III	O
clinical	O
trials	O
were	O
designed	O
to	O
establish	O
the	O
potential	O
role	O
of	O
vorapaxar	O
in	O
treatment	O
of	O
CAD	B-DS
patients	O
.	O

TRA	O
*	O
CER	O
(	O
71	O
)	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
multicenter	O
phase	O
III	O
trial	O
designed	O
to	O
determine	O
whether	O
vorapaxar	O
(	O
40	O
-	O
mg	O
loading	O
dose	O
,	O
followed	O
by	O
2	O
.	O
5	O
mg	O
daily	O
for	O
at	O
least	O
1	O
year	O
)	O
can	O
lead	O
to	O
further	O
reduction	O
in	O
ischemic	O
events	O
when	O
added	O
to	O
standard	O
medical	O
treatment	O
in	O
NSTEMI	O
patients	O
.	O

As	O
an	O
estimate	O
,	O
19	O
,	O
000	O
subjects	O
are	O
required	O
to	O
achieve	O
adequate	O
power	O
.	O

Primary	O
composite	O
end	O
-	O
point	O
is	O
the	O
effect	O
on	O
cardiovascular	O
death	O
,	O
AMI	B-DS
,	O
stroke	B-DS
,	O
recurrent	O
ischemia	B-DS
with	O
hospitalization	O
,	O
urgent	O
PCI	O
,	O
and	O
bleeding	O
.	O

TRA	O
2	O
°	O
P	O
-	O
TIMI	O
50	O
(	O
72	O
)	O
will	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
vorapaxar	O
during	O
long	O
-	O
term	O
treatment	O
of	O
patients	O
with	O
established	O
atherosclerotic	B-DS
disease	I-DS
receiving	O
standard	O
therapy	O
(	O
up	O
to	O
27	O
,	O
000	O
patients	O
).	O

The	O
study	O
targeted	O
patients	O
with	O
a	O
documented	O
history	O
of	O
AMI	B-DS
or	O
stroke	B-DS
within	O
2	O
weeks	O
to	O
12	O
months	O
before	O
the	O
time	O
of	O
inclusion	O
.	O

Patients	O
with	O
peripheral	B-DS
artery	I-DS
disease	I-DS
(	O
PAD	B-DS
)	O
are	O
eligible	O
for	O
inclusion	O
if	O
they	O
have	O
intermittent	O
claudication	O
in	O
conjunction	O
with	O
an	O
ankle	O
-	O
brachial	O
index	O
<	O
0	O
.	O
85	O
or	O
previous	O
revascularization	O
for	O
limb	B-DS
ischemia	I-DS
.	O

Participants	O
are	O
randomized	O
to	O
receive	O
vorapaxar	O
(	O
2	O
.	O
5	O
mg	O
daily	O
)	O
or	O
placebo	O
in	O
addition	O
to	O
standard	O
therapy	O
for	O
at	O
least	O
1	O
year	O
.	O

The	O
primary	O
composite	O
end	O
-	O
point	O
is	O
cardiovascular	O
death	O
,	O
AMI	B-DS
,	O
stroke	B-DS
,	O
or	O
urgent	O
coronary	O
revascularization	O
,	O
whereas	O
the	O
evaluation	O
of	O
long	O
-	O
term	O
safety	O
includes	O
bleeding	O
events	O
defined	O
by	O
the	O
GUSTO	O
and	O
TIMI	O
criteria	O
.	O

Future	O
antiplatelet	O
drugs	O

In	O
addition	O
to	O
the	O
antiplatelet	O
drugs	O
reported	O
above	O
,	O
there	O
is	O
a	O
continuous	O
effort	O
to	O
identify	O
newer	O
targets	O
toward	O
which	O
to	O
direct	O
pharmacological	O
strategies	O
.	O

Gas6	B-GP
(	O
growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
gene	I-GP
6	I-GP
),	O
a	O
member	O
of	O
the	O
family	O
of	O
vitamin	B-GP
K	I-GP
-	I-GP
dependent	I-GP
proteins	I-GP
,	O
is	O
stored	O
in	O
platelet	O
α	O
granules	O
and	O
is	O
released	O
upon	O
activation	O
(	O
73	O
).	O

Although	O
it	O
has	O
a	O
44	O
%	O
sequence	O
homology	O
with	O
protein	B-GP
S	I-GP
,	O
it	O
does	O
not	O
show	O
any	O
anticoagulant	O
activity	O
(	O
74	O
).	O

Being	O
a	O
growth	O
factor	O
-	O
like	O
molecule	O
,	O
as	O
it	O
interacts	O
with	O
receptor	B-GP
tyrosine	I-GP
kinases	I-GP
(	O
RTKs	B-GP
)	O
of	O
the	O
Tyro3	B-GP
,	O
Axl	B-GP
,	O
and	O
MerTK	B-GP
(	O
TAM	O
)	O
family	O
,	O
Gas6	B-GP
employs	O
a	O
unique	O
mechanism	O
of	O
action	O
,	O
interacting	O
through	O
its	O
vitamin	B-GP
K	I-GP
-	I-GP
dependent	I-GP
Gla	I-GP
module	O
with	O
phosphatidylserine	O
-	O
containing	O
membranes	O
and	O
through	O
its	O
carboxy	O
-	O
terminal	O
LG	O
domains	O
with	O
the	O
TAM	B-GP
membrane	I-GP
receptors	I-GP
.	O

Studies	O
indicate	O
an	O
association	O
between	O
Gas6	B-GP
and	O
stroke	B-DS
.	O

Inhibition	O
of	O
Gas6	B-GP
function	O
can	O
be	O
achieved	O
by	O
Gas6	B-GP
-	O
neutralizing	O
antibodies	O
,	O
by	O
proteases	O
cleaving	O
the	O
extracellular	O
domain	O
of	O
Gas6	B-GP
receptors	I-GP
,	O
or	O
by	O
inactivation	O
of	O
RNA	O
for	O
Gas6	B-GP
or	O
Gas6	B-GP
receptors	I-GP
.	O

Antibodies	O
to	O
the	O
carboxy	O
-	O
terminal	O
part	O
of	O
Gas6	B-GP
,	O
responsible	O
for	O
the	O
binding	O
to	O
its	O
receptors	O
,	O
inhibit	O
the	O
aggregation	O
of	O
human	B-OG
platelets	O
induced	O
by	O
ADP	O
(	O
75	O
).	O

Matrix	B-GP
metalloproteinases	I-GP
(	O
MMPs	B-GP
)	O
are	O
involved	O
in	O
tissue	O
remodeling	O
and	O
in	O
the	O
progression	O
of	O
atherosclerosis	B-DS
(	O
76	O
).	O

Human	B-OG
platelets	O
contain	O
MMP	B-GP
-	I-GP
2	I-GP
in	O
their	O
cytosol	O
and	O
release	O
them	O
upon	O
aggregation	O
(	O
77	O
).	O

Active	O
MMP	B-GP
-	I-GP
2	I-GP
,	O
potentiating	O
phosphoinositide	B-GP
-	I-GP
3	I-GP
kinase	I-GP
activation	O
,	O
amplifies	O
platelet	O
aggregation	O
induced	O
by	O
a	O
variety	O
of	O
agonists	O
in	O
an	O
aspirin	O
-	O
or	O
ADP	B-GP
-	I-GP
receptor	I-GP
antagonist	O
-	O
independent	O
fashion	O
(	O
78	O
).	O

MMP	B-GP
-	I-GP
2	I-GP
-	O
neutralizing	O
antibodies	O
have	O
shown	O
protective	O
effects	O
in	O
hearts	O
exposed	O
to	O
ischemia	B-DS
-	I-DS
reperfusion	I-DS
injury	I-DS
(	O
79	O
).	O

MMP	B-GP
-	I-GP
2	I-GP
gene	O
-	O
silencing	O
techniques	O
(	O
80	O
)	O
may	O
be	O
exploited	O
to	O
gain	O
cell	O
-	O
selective	O
MMP	B-GP
-	I-GP
2	I-GP
inhibition	O
.	O

The	O
CD40	B-GP
ligand	I-GP
(	O
CD40L	B-GP
;	O
CD	B-GP
154	I-GP
)	O
is	O
a	O
trans	B-GP
-	I-GP
membrane	I-GP
protein	I-GP
expressed	O
on	O
the	O
surface	O
of	O
activated	O
platelets	O
.	O

Following	O
its	O
exposure	O
,	O
an	O
exodomain	O
(	O
soluble	O
CD40	B-GP
ligand	I-GP
,	O
sCD40L	B-GP
)	O
is	O
released	O
and	O
binds	O
to	O
integrin	B-GP
αIIbβ3	I-GP
on	O
activated	O
platelets	O
,	O
thus	O
promoting	O
thrombus	O
stabilization	O
(	O
81	O
).	O

Therapeutic	O
targeting	O
of	O
the	O
CD40	B-GP
-	O
CD40L	B-GP
axis	O
using	O
humanized	O
anti	O
-	O
CD40L	B-GP
antibodies	O
has	O
already	O
been	O
attempted	O
(	O
82	O
).	O

Shedding	O
of	O
sCD40L	B-GP
from	O
the	O
surface	O
of	O
activated	O
platelets	O
can	O
be	O
prevented	O
by	O
an	O
anti	O
-	O
CD40L	B-GP
antibody	O
(	O
G28	B-GP
-	I-GP
5	I-GP
).	O

This	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
sCD40L	B-GP
and	O
,	O
in	O
turn	O
,	O
blunt	O
platelet	O
reactivity	O
(	O
83	O
).	O

In	O
addition	O
to	O
the	O
production	O
by	O
platelets	O
,	O
PGE2	O
is	O
also	O
produced	O
by	O
other	O
cells	O
in	O
blood	O
,	O
including	O
monocytes	O
.	O

Low	O
concentrations	O
of	O
PGE2	O
potentiate	O
platelet	O
aggregation	O
by	O
priming	O
protein	B-GP
kinase	I-GP
C	I-GP
activation	O
and	O
by	O
inhibiting	O
ade	B-GP
-	I-GP
nylylcyclase	I-GP
.	O

The	O
facilitating	O
effects	O
of	O
PGE2	O
on	O
platelets	O
are	O
mediated	O
by	O
EP3	O
(	O
84	O
,	O
85	O
).	O

In	O
animal	O
studies	O
,	O
DG041	O
,	O
a	O
novel	O
first	O
-	O
in	O
-	O
class	O
antagonist	O
of	O
EP3	O
,	O
effectively	O
inhibits	O
platelet	O
aggregation	O
without	O
increasing	O
the	O
bleeding	O
time	O
(	O
86	O
).	O

In	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
peripheral	B-DS
arterial	I-DS
disease	I-DS
,	O
DG041	O
was	O
found	O
to	O
reduce	O
platelet	O
activation	O
(	O
87	O
).	O

Conclusions	O

Major	O
limitations	O
of	O
current	O
antiplatelet	O
drugs	O
include	O
risk	O
of	O
bleeding	O
,	O
significant	O
interindividual	O
variability	O
in	O
the	O
response	O
,	O
and	O
extended	O
duration	O
of	O
action	O
that	O
cannot	O
be	O
reversed	O
if	O
the	O
need	O
for	O
hemostasis	O
or	O
emergency	O
surgery	O
arises	O
.	O

Newer	O
anti	O
-	O
platelet	O
drugs	O
have	O
addressed	O
some	O
but	O
not	O
all	O
these	O
limitations	O
.	O

Dual	O
antiplatelet	O
treatment	O
has	O
only	O
been	O
efficacious	O
in	O
acute	B-DS
coronary	I-DS
syndromes	I-DS
.	O

In	O
addition	O
,	O
newer	O
thienopyridines	O
did	O
not	O
show	O
advantages	O
over	O
and	O
above	O
those	O
of	O
ticlopidine	O
or	O
clopidogrel	O
as	O
to	O
reduction	O
of	O
stroke	B-DS
.	O

Because	O
of	O
its	O
pharmacodynamic	O
characteristics	O
,	O
prasugrel	O
is	O
more	O
efficacious	O
in	O
preventing	O
ischemic	O
events	O
in	O
patients	O
with	O
ACS	B-DS
undergoing	O
PCI	O
,	O
but	O
with	O
increased	O
bleeding	O
complications	O
.	O

The	O
same	O
concept	O
is	O
true	O
for	O
ticagrelor	O
.	O

Platelet	O
activation	O
by	O
thrombin	B-GP
is	O
distinct	O
and	O
appears	O
to	O
be	O
less	O
important	O
for	O
hemostasis	O
than	O
fibrin	B-GP
generation	O
(	O
preclinical	O
data	O
).	O

Accordingly	O
,	O
inhibition	O
of	O
PAR	B-GP
-	I-GP
1	I-GP
function	O
rather	O
than	O
inhibition	O
of	O
fibrin	B-GP
generation	O
or	O
activity	O
may	O
provide	O
a	O
newer	O
strategy	O
for	O
treatment	O
of	O
thrombotic	B-DS
disorders	I-DS
in	O
humans	B-OG
(	O
88	O
).	O

Individual	O
bleeding	O
risk	O
,	O
however	O
,	O
has	O
to	O
be	O
further	O
defined	O
,	O
as	O
this	O
would	O
be	O
the	O
first	O
antiplatelet	O
drug	O
in	O
which	O
a	O
greater	O
efficacy	O
is	O
not	O
associated	O
with	O
a	O
worse	O
safety	O
(	O
greater	O
bleeding	O
tendency	O
).	O

A	O
concerted	O
effort	O
that	O
takes	O
into	O
consideration	O
clinical	O
,	O
genetic	O
,	O
and	O
laboratory	O
information	O
represents	O
a	O
major	O
direction	O
to	O
be	O
pursued	O
in	O
order	O
to	O
tailor	O
the	O
therapeutic	O
approach	O
for	O
individual	O
patients	O
.	O

The	O
results	O
of	O
on	O
-	O
going	O
clinical	O
trials	O
and	O
the	O
identification	O
of	O
further	O
potentially	O
useful	O
targets	O
for	O
antiplatelet	O
treatment	O
(	O
87	O
)	O
will	O
hopefully	O
help	O
address	O
this	O
issue	O
.	O

